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ABSTRACT
It has been shown that methionine depletion inhibits tumor cell growth and
reduces tumor cell survival. The main purpose of this project is to examine three fusion
proteins for targeting human cancer cells selectively and inhibiting the migration and
proliferation of the cancer cells. The fusion proteins studied are ATF-methioninase
(amino-terminal fragment of urokinase, amino acids 1-49, linked to the amino terminus
of L-methioninase fro Pseudomonas putida), TGF-methioinase (human transforming
growth factor- linked to L-methioninase), and methioninase-annexin V (L-methioninase
linked to the amino terminus of human annexin V). The three fusion proteins were
expressed as soluble proteins and purified to near homogeneity. Flash freezing and
followed by lyophilization was found to be most effective way to store fusion protein
samples.
The influence of the fusion protein on the growth and motility of human breast
cancer cells, SK-LU-1 human lung cancer cells, and PC-3 human prostate cancer cells
was examined using a culture wounding assay. ATF-methioninase inhibited the
proliferation and migration of all cancer cell lines. For MCF-7 breast cancer cells, the
inhibition by ATF-methioninase was much greater than for either free L-methioninase or
mutated ATF-methioninase (mutated to give inactive enzyme). TGF-methioninase
inhibited the proliferation and migration in MCF-7 and PC-3 cancer cells. However, the
inhibition was significantly greater for ATF-methioninase compared to TGF-
methioninase, especially at treatment days 2 and 3.
ATF-methioninase binding to MCF-7 cells was measured by
immunocytochemical localization. MCF-7 tumor xenograft growth was measured in nude
xii
mice for the mice treated with ATF-methioninase and L-methioninase. Treatment of s.c.
implanted MCF-7 breast cancer cells mouse xenografts with ATF-methioninase gave
significantly more tumor regression when compared to mouse xenografts treated with L-
methioninase alone or with the vehicle control.
The methioninase-annexin V fusion protein bound specifically to
phosphatidylserine (PS) immobilized on plastic plates, as well as on the surface of MCF-
7 cancer cells in which PS was induced to be on the surface by the addition of hydrogen
peroxide.
11. INTRODUCTION
Cancer is the one of the leading causes of mortality in United States of America.
The rates of cancer began to fall in the U.S.A., about 13 years ago (Figure 1.1), but
cancers still account for major percentage of total deaths in this country. In 2006,
estimated cancer related deaths are 560,000 according to the American Cancer Society
(ACS). Based on the estimated number of new cases of cancers for the year 2006, the top
five types of cancer are as follows: prostate, breast, lung, colon, and urinary bladder.
A most feared and dangerous aspect of cancer is metastasis, where cells break
away from the primary tumor site, invade local tissues and vessels, and establish new
cancer colonies at distant sites. Key steps in the metastatic cascade include cell
proliferation, regulated expression of extra-cellular matrix degrading enzymes, active
movement through tissues, invasion through basement membranes into blood or lymph
vessels, dissemination to distant locations, and invasion and movement into a target
organ, where the cancer cells once again proliferate to form a secondary tumor [1, 2]. The
formation of new blood vessels, angiogenesis, is a requirement for the growth of primary
tumors and secondary tumors. The primary tumors itself are not lethal, but it is the
metastatic spread of tumor cells to other sites, especially brain, that is lethal.
Unfortunately, many tumors, like breast tumors are detected that may have already
metastasized to new sites.
Curing cancer requires eliminating all cancer cells. Chemotherapy, radiotherapy,
gene therapy, and surgery are some of the treatments for cancer [3]. Most treatment
methods cannot prevent the spread of cancer in the body by metastases, which lead to
numerous tumors around the body. Chemotherapy has been used widely to treat the
2Figure 1.1. Age-adjusted cancer death rates, for males (Top) and for females (bottom),
U.S. 1930-2002 (Source: ACS, Cancer Statistics 2006)
3disseminated cancers, but the risk factor for damaging other normal tissues is high.
Surgical removal of cancer tissue has been effective in breast and prostate cancers but has
failed in curing widely disseminated cancers. In gene therapy, delivery of a gene is
achieved by polymer capsules, liposomes, viruses, microinjections and electroporation
[4-7]. Delivery systems of viral origin, such as adenoviruses and retroviruses, are widely
used for gene therapy because of their high transfection efficiency. However, viral
vectors have various disadvantages, which include toxicity and high levels of
immunogenicity that restrict the repeated use of these delivery systems.
Since most of these therapies are not cancer specific, the ultimate goal of cancer
therapy is to develop agents that will selectively destroy cancer cells, sparing the normal
tissues of the patient. The major goal of this work is to develop a therapeutic anticancer
agent which targets specifically to cancer cells and to test the effectiveness to kill the
cancer cells or prevent them from growing.
The following section is an overview of the dependency of cancer cells on
methionine and is followed by a description of the anticancer effects by L-methioninase
from Pseudomonas putida. Then a review is given of three targets on the surface of
cancer cells: urokinase receptor, epidermal growth factor receptor, and phosphatidyl
serine. Finally, the experimental hypothesis and experimental design are discussed for
three fusion proteins designed to bind to these three targets.
4Methionine Dependency in Cancer Cells
Methionine is an essential nonpolar amino acid. It has many major functions: 1)
the methionine derivative S-adenosyl methionine (SAM) serves as a methyl donor [8-10];
2) it is required for the formation of polyamines, which have specific roles in embryonic
development, cell cycle, cancer, neurochemistry as well as pulmonary and immune
system functions; [11] 3) it plays a role in cysteine, carnitine and taurine synthesis; 4) it is
incorporated into the N-terminal position of all proteins in eukaryotes, although it is
usually removed after post translation modifications; 5) it is a precursor of glutathione, an
antioxidant, that protects cells from toxins such as free radicals [12].
Over the decades, many metabolic anomalies are commonly found in solid
tumors. Among the metabolic abnormalities recurrently found in cancers, methionine
dependency and alterations of methionine metabolism have been found in many, if not in
all, types of human tumors [13-20]. Methionine dependence is defined as the inability or
reduced ability of cancer cells when compared with normal cells to proliferate when
amino acid methionine is replaced by its immediate precursor homocysteine.
Homocysteine is a non-standard amino acid that has the same structure as methionine
except that it lacks a methyl group (Figure 1.2). All normal cells like fibroblasts, kidney,
liver, and epithelial cells have been shown to be methionine independent [13, 15, 16].
Numerous tumor cell lines like breast, lung, colon, kidney, bladder, melanoma, and
gliablastoma have been shown to be methionine dependent [15, 21, 22].
The biochemical basis of methionine dependence in tumor cells has not been fully
elucidated. One hypothesis is that it is due to the reduced or no synthesis of methionine in
cancer cells due to a deficiency of enzymes responsible for the synthesis of methionine,
5Homocysteine Methionine
Figure 1.2. Structures of homocysteine and methionine
Figure 1.3. Reaction catalyzed by methioninase
CH3SCH2CH2C-NH3+ CH3SH + CH3CH2C-COO-
H
COO-
L-Methioninase
H2O NH4+
O
=
Methionine Methanethiol 2-Ketobutyrate
6methionine synthase or betaine homocysteine methyltransferase. Either of these enzymes
can catalyze the methylation of homocysteine to form methionine in normal cells.
Methionine synthase occurs in all mammalian tissues, while the betaine enzyme is mainly
present in the liver [23]. It was shown that methionine-dependent tumor cell lines have
low amounts or low activity of methionine synthase [24, 25]. Another reason for
methionine dependency could due to higher transmethylation reaction rates by
methionine dependent tumor cells when compared to normal cells. Methionine plays an
important role in the synthesis of methyl donor S-adenosylmethionine (SAM) which is a
cofactor for transmethylation reactions. SAM donates a methyl group to form S-
adenosylhomocysteine, and also SAM plays a pivotal role as a methyl donor in a myriad
of biological and biochemical events [10]. Elevated transmethylation reaction rates
suggest that tumor cells depend on exogenous methionine for the survival and
proliferation [20]. Finally this methioninine dependency could be due to non-
conservation of methionine in cells which is achieved by methylthioadenosine
phosphorylase, which functions solely in polyamine pathway of cells by removing
methylthioadenosine product from both spermidine synthase and spermine synthase [23].
Methioninase as Anticancer Agent
L-Methioninase is a pyridoxal 5’-phosphate (PLP) enzyme that catalyses ,  –
elimination and -replacement of L-methionine and its S-substituted derivatives as shown
in Figure 1.3. This enzyme was found in the extracts of a soil bacterium, Clostridium sp,
Pseudomonas sp, rumen bacteria, and Aeromonas sp. The enzyme was initially isolated
from Clostridium sporgenes [26]; later it was isolated from Pseudomonas putida [27].
The L-methioninase gene, from Pseudomonas putida, was cloned in Escherichia coli and
7milligram quantities were isolated [28]. L-methioninase from Pseudomonas putida is
known to exist as homotetramer form (Figure 1.4), and its quartenary structure is
observed in the crystal structure (Figure 1.4) [29, 30]. Each monomer consists of 398
amino acids and contains a PLP molecule as cofactor, which is covalently linked to Lys
211. Each monomer consists of three domains with an N-terminal domain (residues 1-63)
comprising of an -helix and loop of 46 residues, a PLP binding domain (residues 64-262)
comprising of seven parallel -strands, and the C-terminal domain (residues 263-398)
comprising of five anti parallel -strands [29, 30] as shown in Figure 1.5. Cys116 of L-
methioninase is a nucleophilic residue and is expected to play a key role in enzymatic
reactions. It was also shown that when Tyr114 of L-methioninase is mutated to Phe114,
then the enzymatic activity of L-methioninase decreased by 910 fold [31], suggesting that
Tyr114 plays a critical role in the catalytic mechanism.
Various studies of using L-methioninase for treatment of animal and human
subjects have been carried out. In two studies, i.v. infusion of L-methioninase for 24
hours to nine patients with advanced lung, breast or kidney cancer, or lymphoma in a
phase I clinical trial resulted in serum methionine being reduced to very low levels, with
no adverse effects observed [19]. L-Methioninase enzyme treatment in combination with
chemotherapeutic agents such as cisplatin, 5-fluorouracil, and 1,3-bis(2-chloroethyl)-1-
nitrosoureal have shown efficacy and synergy, in mouse models of colon cancer, lung
cancer, and brain cancer [32-35]. L-Methioninase treatment in combination with the
addition of the L-methioninase gene using a retroviral vector showed a synergistic effect
8Figure 1.4. Homotetramer structure of L-methioninase. Each color represents each
monomer of L-methioninase [30].
9Figure 1.5. Structure of L-methioninase, The N-terminal domain is held in blue, the PLP-
binding domain in yellow and the C-terminal domain in red. PLP and PLP-binding
Lys211 are shown in a ball and stick representation [30].
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on human ovarian cancer cells and human fibro sarcoma cells [36]. L-methioninase has
been successfully conjugated to polyethylene glycol (PEG), resulting in a significant
increase in the serum half-life and a large reduction in immunogenicity in rats and
primates [18, 37-39].
To summarize, due to the antitumor efficacy of L-methioninase in vitro and in
vivo in human tumors xenografted in nude mice and also in humans, L-methioninase has
shown promise as an anticancer agent. By targeting the L-methioninase to cancer cells,
the efficacy of cancer treatment should be improved by reducing the dose level and
immune response. The dose can be reduced because the L-methioninase will accumulate
on the cancer cell surface, where it will degrade methionine coming in contact with the
cell surface. This will require less enzyme than for non-targeted enzyme, which must
always be in the fluid surrounding the cells in order to be effective. The immune response
can possibly be reduced because this treatment is designed to localize L-methioninase in
the tumor, rather than it being delivered to the entire body.
Selectivity to cancer cells is achieved usually by fusing or attaching the anticancer
agent to a ligand or molecule, which can target specifically to cancer cells. This
selectivity is achieved by three ways. The first way is to use an antibody which can
specifically target the antigenic moieties that are not detectable or minimally present on
cells in normal cells but present in greater quantities on cancer cells. So far only few
antigens have been really specific to cancers cells (tumor specific antigens (TSA)).
Antibodies against TSAs like clone-specific idiotypic immunoglobulin on the surface of
the malignant B cells and clone-specific T-cell antigen-receptor protein on malignant T
cells are used mainly in this kind of treatment [40-42]. The second way of selectivity is
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based on recognition of cell surface-associated molecules that are overexpressed and
abundant on cancer cells. These surface-associated molecules include lectins, growth
factors (epidermal growth factor, insulin like growth factor), cytokines, hormones, and
low-density lipoproteins [43-45]. The third way of targeting cells is by targeting
endothelial cells of the vasculature of the tumor. Vascular endothelial cells in tumors
differ from normal cells in their metabolic pathways, gene expression, and
immunological and biochemical characteristics [46-48]. The ligand-based vascular
targeting agents include fusion proteins (e.g., vascular endothelial growth factor linked to
gelonin), immunotoxins (e.g., monoclonal antibodies to endoglin linked to ricin,
antibodies linked to cytokines or coagulant proteins), and liposomally encapsulated
drugs.
In this project, the second and third ways were used to target L-methioninase
(anticancer agent) to cancer cells by fusing with the peptides or protein which would
target to overexpressed receptors on cancer cells and endothelial cells of the tumor
vasculature. The amino terminal fragment (ATF) of urokinase and transforming growth
factor- (TGF-) were used to target the urokinase plasminogen activator receptors and
the epidermal growth factor receptors of cancer cells. Annexin V was used to target
tumor vasculature endothelial cells. The rationale for selecting these peptides or proteins
is explained in the following sections.
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Urokinase Plasminogen Activator Receptor as a Target on Cancer Cells
The serine protease urokinase-type plasminogen activator system plays an
important role in the mediation of extracellular proteolytic degradation activity. This
system consists of the serine protease urokinase (uPA), urokinase plasminogen activator
receptor (uPAR), plasminogen activator inhibitors (PAIs), and the proenzyme
plasminogen. uPA is the two chain molecule which is formed after cleavage of single
chain pro-uPA by plasmin. The system gets activated by uPA bound to uPAR by
converting plasminogen to plasmin and initiating the signaling cascades (Figure 1.6).
This signaling cascade is only initiated in cell types like leukocytes, smooth muscle cells,
and endothelial cells which have a role of inflammation, angiogenesis and wound repair.
The uPAR consists of three domains and it is attached to outer cell membrane by
a glycosyl phosphatidylinositol (GPI). It is a 50-60 kDa glycoprotein, with protein
contributing to 31.5 kDa of the mass. It has three domains (D1, D2, and D3). The N-
terminus of the uPAR is the primary site for the binding of amino terminal fragment
(ATF) of uPA, but all the three domains are important for high affinity binding of uPA to
uPAR. The three domains form a concave shape having a cone-shaped cavity at center.
Most normal cells have little or no detectable uPAR, with some exceptions [49]. uPAR is
expressed in hematopoietic cells, such as monocytes, eosinophils, neutrophilic
granulocytes, skin mast cells, dendritic cells, and T-lymphocytes. It is found expressed in
non-hematopoietic cells, such as endothelial cells, hepatocytes, fibroblasts, keratinocytes,
smooth muscle cells, and placental trophoblasts [49]. uPAR is overexpressed in variety of
cancer tissues, like breast, colon, kidney, liver, lung, oral mucosa, and ovary [50-58].
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Figure 1.6. The uPA/uPAR system. The pro-uPA binds to uPAR, which is converted to
active uPA after cleavage by plasmin. Active uPA is responsible for converting
plasminogen to plasmin, which is responsible for degradation of extracellular matrix [59].
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Pro-uPA has 411 amino acids (Figure 1.7). The amino terminal fragment (ATF)
consists of 135 amino acids, containing a growth factor (GF) domain (10-40 amino acids)
joined by a triple disulfide kringle domain (90 amino acids) [60, 61]. The C-terminal 253
amino acids comprise the serine protease domain. Pro-uPA is cleaved to give an active
protein (uPA) by plasmin at Lys158, leaving A and B chains joined via disulfide linkages
as shown in Figure 1.7. Residues 12-32 in the GF domain of chain A of uPA play a key
role in binding to its receptor uPAR, and the GF domain shares sequence homology of
the GF domain with epidermal growth factor (EGF) [60, 61]. The catalytic portion of
uPA is necessary for the internalization of the uPA and signaling cascade [62]. It has also
been shown that blocking the cell surface activity of uPA with an inactive uPA causes a
reduction in metastasis by cancer cells [63].
PAI-1 is the major inhibitor of urokinase activity in plasma and in most tissues.
Binding of the PAI-1 to pro-uPA forms an inactive, reversible complex which is a stable
noncovalently-linked intermediate [49]. Binding of PAI-1 to pro-uPA is controlled by the
amount of plasminogen, which inhibits the reaction, as well as on the concentration of
vitronectin. PAI-1 possesses a vitronectin binding site and competes with uPAR for
vitronectin binding [49, 64].
The ATF of uPA is an excellent choice to fuse it with L-methioninase for three
reasons: (1) It will bind to a receptor that is overexpressed on many types of cancer cells.
(2) It will not be internalized and will thus keep L-methioninase at the cell surface to
prevent methionine from entering the cell. (3) It will prevent uPAR from binding to uPA
and thus reduce metastasis and migration through tissue. Using this approach, a
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Figure 1.7. Amino acid sequence of pro-urokinase (Pro-uPA). Cleavage by plasmin
protease is indicated by arrow. Dashes represents the position of disulfide bonds [65].
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synergistic inhibition of cancer cell migration and proliferation should be able to be
achieved from the inactivation of the urokinase receptor as well as from the methioninase
activity on cancer cells.
Epidermal Growth Factor Receptor as Target on Cancer Cells
EGFR is a 170 kDa single linear transmembrane glycoprotein consisting of a
ligand binding extracellular domain (cysteine rich domains) and a cytoplasmic domain
encoding tyrosine kinase, where these domains are linked through a hydrophobic
membrane anchor sequence. Binding of a stimulatory ligand (like EGF or transforming
growth factor-, TGF-) to the extracellular domain results in receptor dimerization and
autophosphorylation of EGFR, which initiates the intracellular transduction [66] (Figure
1.8). Autophosphorylated EGFR also activates the proteins required for endocytosis and
finally leads to internalization of EGFR [67-69]. It has been suggested that
overexpression of the EGF receptor in tumor cells provides a mechanism for autocrine
growth stimulation leading to uncontrolled growth and cellular transformation, although
oncogenic transformation through the EGF receptor only occurs in the presence of excess
ligand [70]. The exact role of the EGF receptor in metastasis is not known, but it has been
observed that more malignant tumors express higher amounts of cell surface EGF
receptors [71]. EGFR is overexpressed in head and neck squamous cell cancer and
cervical, renal cell, lung, prostate, bladder, colorectal, pancreatic, breast cancer,
melanoma, glioblastoma, and meningioma [72-77]. This receptor has been targeted by a
fusion protein consisting of the TGF- binding peptide linked to Pseudomonas exotoxin
with its binding domain removed [78]. The problem with this approach is that normal
cells with the receptors bound by the fusion protein are also killed, resulting in potentially
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Figure 1.8. Epidermal growth factor receptor [79]. Binding of EGF or TGF- to
EGFR autophosphorylates the cytoplasmic domain of EGFR and triggers signal for
proliferation.
18
severe side effects. TGF- is a 51 amino acid peptide with a molecular weight of 6 kDa,
which binds to EGFR with the same affinity as EGF for mammalian cells and is chosen
as a targeting peptide in the fusion protein (TGF-methioninase). Comparison of targeting
TGF-methioninase and ATF-methioninase to cancer cells will enable a determination of
the importance of internalization by the targeted receptor to the effectiveness of treatment.
Phoshatidylserine (PS) as Target on Tumor Vasculature Endothelium
In mammalian cells, the phosphatidylserine (PS) content is higher in the plasma
membrane than other organelles. When normal cells are under no stress, PS is exclusively
located on the cytoplasmic side of the plasma membrane [80, 81]. Once cells are
activated by certain stimuli, PS is rapidly externalized on the cell surface, followed by
various physiological extracellular events. This asymmetry of PS is controlled by the
ATP-dependent enzyme aminophospholipid translocase, which transports the PS to the
cytoplasm and Ca2+ dependent enzyme scramblase, which in turn transports PS from the
cytoplasm to the external surface of the cell [82, 83]. Loss of PS asymmetry is observed
under different pathologic and physiologic conditions, including apoptosis, cell aging,
intercellular fusion of myoblasts and trophoblasts, cell migration, activation of platelets,
and cell degranulation [84-88]. Spontaneous PS exposure has been observed also in
malignant cells in the absence of exogenous activators or cell injury [82, 83]. Exposure of
PS is also observed in vascular endothelial cells and could be due to
hypoxia/reoxygenation, acidity, thrombin, inflammatory cytokines, and reactive oxygen
species in stress conditions which may generate Ca2+ fluxes in the tumor vascular
endothelium that activate scramblase or inhibit aminophospholipid translocase [89, 90].
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It has been previously shown that anionic phospholipids become exposed on the
vascular endothelium of blood vessels in mice bearing various types of solid tumors [89,
90]. This was demonstrated by generating a rat immunoglobulin M monoclonal antibody,
9D2, directed against anionic phospholipids and administering it i.v. to the mice. Due to
abundant availability of PS on tumor endothelial cells and its absence in normal
endothelium cells, it has been studied as a target for cancer therapy.
Annexin V is a 36 kDa protein which binds specifically to PS in the presence of
calcium. Annexin V has been crystallized and shown to have a single subunit structure
with four tandem repeats [91]. It has also been shown that annexin V binds to the tumor
vascular endothelium but not the normal vascular endothelium [89].
In this project, a fusion protein is designed to target L-methioninase to the tumor
vasculature by fusing annexin V to the C-terminus of L-methioninase. The reasons why
this design is advantageous are as follows: (1) The fusion protein can be administered i.v.,
which is much easier than administering L-methioninase directly to the cancer cells. (2)
The fusion protein will bind to the surface of the tumor vasculature and prevent
methionine in the bloodstream from reaching the tumor. The dosages required should be
low since the fusion protein will be binding only to the tumor vasculature.
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Experimental Hypothesis and Experimental Design
Based on this literature review, the hypotheses of this study are: (1) ATF-
methioninase, TGF-methioninase, and methioninase-annexin V fusion proteins will be
expressed in E. coli in soluble and active form, (2) these fusion proteins will bind
selectively to cancer cells, (3) ATF-methioninase, TGF-methioninase, and methioninase-
annexin V proteins would selectively kill the cancers or cause cell growth to be inhibited
both in vitro and in vivo. These hypotheses were tested using the following experimental
design:
1. Construction and expression of fusion protein genes. Three fusion protein genes
will be constructed by using the polymerase chain reaction. These genes will be cloned
and expressed recombinantly in E. coli. The general structure of fusion proteins are
shown in the Figure 1.9. The number of amino acid residues and molecular weights of
all the fusion proteins are shown in Table 1.1. All the fusion proteins have a flexible
linker (Gly-Ser-Gly-Ser-Gly-Ser), where the two proteins are fused without disturbing
their function and are not susceptible to degradation by host proteases [92]. The ATF and
TGF- are placed at the N-terminus of the fusion protein so that the binding domains of
either ATF or TGF- are not disturbed. Annexin V was placed at C-terminus since the
binding domain of annexin V is located at the C-terminus. ATF-methioninase was
already expressed and purified in this lab previously [93]. So ATF-methioninase, TGF-
methioninase, and methioninase-annexin fusion proteins are expected to form soluble
proteins because each fusion contains a large known soluble protein, L-methioninase.
The solubility of these proteins will be analyzed by the Bradford assay for total protein
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General Fusion Protein Design
Specific Fusion Proteins
Figure 1.9. General structure of the fusion proteins (not to scale) constructed for
this study. ATF is the N-terminal 1-49 amino acids of the urokinase A chain. TGF- is
the transforming growth factor-.
Protein 1
Flexible
Linker
Protein 2
ATF 6 kDa
TGF- 6kDa Methioninase 43 kDa
Annexin V 36 kDaMethioninase 43 kDa
Methioninase 43 kDa
ATF 6 kDa Mutated Methioninase 43 kDa
N- 
N- 
N- 
N- 
N- 
-C 
-C 
-C 
-C 
-C 
22
Protein Residues Molecular Weight (KDa)
ATF-methioninase 452 48.5
Mutated ATF-methioninase 452 48.5
TGF-methioninase 454 48.6
Methioninase-annexin V 719 78.5
Table 1.1. Molecular weight and number of amino acid residues of fusion proteins.
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and sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) to separate the
proteins.
Amino acids 1-49 of the ATF are used since this region includes residues 12-32
that have been shown to be critical for binding to the urokinase receptor [60]. The kringle
domain of urokinase A chain is excluded because this domain has been shown to bind
heparin, which could bind polyanionic molecules such as proteoglycans and aid in the
invasion of tissue [94]. This is the main reason to choose ATF with 1-49 amino acids
over ATF with 1-135 amino acids.
2. Examination and determination of anticancer effects of ATF-methioninase and
TGF-methioninase on cancer cells. Anticancer effects of these fusion proteins will be
studied using the cell culture wounding model [93]. It is anticipated that targeting TGF-
methioninase to its internalizing receptor EGFR will be less inhibitory to cancer cells
than targeting ATF-methioninase to its non-internalizing receptor uPAR
3. Examination of binding of ATF-methioninase to MCF-7 breast cancer cells.
Previously it has been shown that ATF-methioninase binds specifically to MCF-7 breast
cancer cells [93]. In this present study, the specific binding of ATF-methioninase fusion
protein to cancer cells will be demonstrated by immunocytochemical localization. It is
expected that ATF-methioninase will bind selectively to cancer cells and that to L-
methioninase will not bind.
4. Effect of targeted L-methioninase on the growth of MCF-7 breast cancer cells in
nude mice. The nude mouse xenograft model will be used to determine the influence of
the ATF-methioninase upon the growth of breast cancer cells in vivo. It is expected that
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the ATF-methioninase will not be cytotoxic to the nude mice and inhibition of tumor
growth will be more effective than L-methioninase treatment alone.
5. Determination of the binding of the methioninase-annexin fusion protein to PS.
This is done using plastic-immobilized PS and using MCF-7 breast cancer cells, in which
PS is induced to be on the cell surface by the addition of hydrogen peroxide. It is
expected that binding will increase as the concentration of methioninase-annexin
increases and that binding of an L-methioninase control will be minimal.
Part of the work presented following this section was published or was in press
prior to the publication of this dissertation [95-97].
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2. MATERIALS
Plasmids and Bacterial Strains
Plasmid pKK223-3 containing the ATF-methioninase fusion gene (pKK223-
3/ATF-METH) was synthesized previously in this lab [93]. Plasmid containing TGF-
was kindly provided by Dr. Ira Pastan of the National Cancer Institute (pVC387/TGF),
and plasmid containing the annexin V-soluble tissue factor fusion gene (pET-
22b(+)/STFANX) was kindly provided by Dr. Stuart Lind of OU Health Sciences Center.
Linear vector pET-30 Ek/LIC (Novagen, Madison, WI) was used for ATF-methioninase,
L-methioninase, methioninase-annexin V, and annexin V gene constructions. A map of
this plasmid showing its general features is shown in Figure 2.1. Linear vector pET-44
Ek/LIC (Novagen) was used for TGF--methioninase fusion gene construction. A map of
this plasmid showing its general features is shown in Figure 2.2. E. coli NovaBlue
singles were used for plasmid amplification. E. coli BL21(DE3) was used as the protein
expression host. E. coli XL1-Blue was used as host for site-directed mutagenesis.
Media for E.coli Cell Cultures
Yeast extract and tryptone for LB media and all other media additives were
purchased from Sigma (St Louis, MO).
26
Figure 2.1.The pET-30 Ek/LIC vector. General features of the pET-30 Ek/LIC vector
(Novagen catalog, 2006).
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Figure 2.2. The pET-44 Ek/LIC vector. General features of the pET-30 Ek/LIC vector
(Novagen catalog, 2006).
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Enzymes
ExpandTM PCR reagents were purchased from Boehringer Mannheim Corp.
(Indianapolis, IN). T4 DNA ligase and restriction enzyme BamHI were purchased from
New England BioLabs (Beverly, MA). T4 DNA polymerase and HRV 3C protease were
purchased from Novagen. DpnI enzyme and PfuTurbo DNA polymerase for site-directed
mutagenesis were purchased from Stratagene (La Jolla, CA).
DNA Synthesis, Purification, and Analysis
Primers for the PCR amplification of the gene fragments were synthesized by the
Molecular Biology Resource Facility at University of Oklahoma Health Sciences Center
(Oklahoma City, OK). All the primers were desalted, analyzed and not purified. The
Qiaquick PCR purification kit, Qiaquick agarose gel purification kit, and Qiaquick
plasmid purification kit were purchased from Qiagen (Valencia, CA). SeaKem® LE
agarose was purchased from Cambrex Bio Science Rockland, Inc.(Rockland, ME). The
1kb DNA ladder and  DNA-BstEII digest ladder were purchased from New England
Biolabs. The sequencing of all the genes was performed by the Oklahoma Medical
Research Foundation (OMRF) DNA sequencing facility using primers that we specified.
SDS-PAGE and Immunoblotting
The PROTEANTM large format and small format electrophoresis cells (Bio-Rad,
Hercules, CA) were used for protein analysis by SDS-PAGE. All the reagents used for
making SDS-PAGE gels were purchased from Bio-Rad. Rabbit anti-L-methioninase
monoclonal primary antibody was produced in purified form and obtained from Sigma
Genosys (St. Louis, MO). Goat anti-rabbit IgG secondary antibody with horseradish
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peroxidase (HRP) conjugated was purchased from Sigma. Nitrocellulose membranes,
NitroBind were purchased from Micron Separations Inc. (Westborough, MA).
Protein Purification
HisTrap chromatography columns (5 ml) were purchased from GE Health Bio-
Sciences Corp. (Piscataway, NJ). Flow adapters were purchased from Bio-Rad. For
detection of proteins at 280 nm, an ISCO UA-5 chart recorder and
absorbance/fluorescence detector with a type-10 optical unit (Isco, Lincoln, NE) were
used. A Gilson MiniPuls 3 peristaltic pump (Gilson Medical Electronics Inc.,
Middletown, WI) was used for chromatography during protein purification. Centriprep
centrifugal filters were from Millipore (Billerica, MA).
Media for Cancer Cell Cultures
MCF-7 human breast cancer cells were obtained from the Michigan Cancer
Foundation (Detroit, Michigan). RPMI 1640 media (without phenol red), 2 mM L-
glutamine, gentamicin, penicillin, streptomycin, and estradiol were all purchased from
Sigma. Bovine calf serum was purchased from Hyclone (Logan, UT). Dulbecco’s
Modified Eagle Medium (DMEM) was purchased from Gibco Life technologies (Grand
Island, NY). Matrigel was obtained from BD Biosciences (Franklin Lakes, NJ).
Cell Binding Assay for ATF-methioninase
Rabbit anti-L-methioninase monoclonal primary antibody was produced in
purified form by Sigma Genosys (St. Louis, MO). Goat anti-rabbit IgG secondary
antibody with HRP conjugated was purchased from Sigma. Hemotoxylin was purchased
from Vector Laboratories (Burlingame, CA).
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Binding Assay for L-Methioninase-Annexin
Phosphotidylserine, O-phenylenediamine (OPD), and phosphate citrate buffer
were purchased from Sigma, and polypropylene plates were purchased from Corning Inc.
(Acton, MA). MCF-7 cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) (Gibco Life technologies) supplemented with fetal calf serum (heat inactivated)
(Atlanta Biologicals, Norcross, GA), 86 mg/mL penicillin, and 86 mg/mL streptomycin
(Invitrogen, Carlsbad, CA). Accutase was purchased from Innovative Cell Technologies,
Inc. (San Diego, CA). Rabbit anti-L-methioninase monoclonal primary antibody was
produced in purified form and obtained from Sigma Genosys. Goat anti-rabbit IgG
secondary antibody with HRP conjugated was purchased from Sigma.
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3. METHODS
Primer Design for PCR
Primers were designed to have a sequence that is a reverse complement of a region
of template or target DNA and also have incorporated sequences (such as ligation
independent cloning sites, HRV 3C protease site, and other restriction enzyme sites).
Following is an example of a set of a primers used to amplify the fusion gene containing
49 amino acids of urokinase and L-methioninase (complete list of all primer sequences is
shown in Appendix A).
Sequence of the 5’ primer for amplifying the urokinase gene:
< LIC site > < HRV 3C Protease site >
5’ - GAC / GAC / GAC / AAG / ATG / CTT / GAA / GTC / CTC / TTT / CAG / GGA /
CCC / AGC / AAT / GAA / CTT / CAT / CAA / GTT / CC – 3’
Complementary to urokinase 5’ end
It should be noted that the gene encoding the LIC site and the gene encoding HRV 3C
protease site were introduced on all fusion genes (primers for respective fusion genes are
listed in Appendix A). The sequence for the 3’ PCR primer is
. LIC site . . Complementary to methioninase.
5’ – GAG / GAG / AAG / CCC / GGT / TAT / CAT / GCA / CAC / GCC / TCC / AAT /
. 3’end .
GCC / AAC / TCG – 3’
The melting temperature (Tm) of primers and the propensity to form dimers with itself or
other primers in the reaction were calculated by using a program provided by the website
http://www.basic.northwestern.edu/biotools/oligocalc.html. The design of primers was
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based on these criteria: 1) length of primers were above 17 bases, 2) G + C composition
was more than 50-60 %, 3) 3’ end of primer was G or C, or CG or GC, 4) Tm of primers
was between 55-80 oC, and 5) ability of primer to form secondary structure was
minimized. All the primers were obtained from Molecular Biology Resource Facility at
the University of Oklahoma Health Sciences Center and were in the desalted state.
Construction of Fusion Genes
ATF-Methioninase and L-Methioninase Genes
A general outline of the ligation independent cloning (LIC) scheme for ATF-
methioninase (pET-30 Ek/LIC/ATF-METH) and L-methioninase (pET-30
Ek/LIC/METH) is shown in Figure 3.1. The DNA sequences encoding the ATF-
methioninase fusion protein and L-methioninase from pKK223-3/ATF-METH [93] were
amplified by the polymerase chain reaction using the Expand High Fidelity PCR system
(Boehringer Mannheim, Indianapolis, IN). The optimal PCR reaction compositions and
thermal cycling parameters are shown in Table 3.1 and Table 3.2. Similar reaction
conditions were used since all the genes were of similar size. Each gene after PCR
reaction was purified by the Qiaquick PCR purification protocol (See Appendix B).
Purified gene was treated with T4 DNA polymerase to create LIC sticky ends on the gene,
and this treated gene was annealed to the pET-30 Ek/LIC linear vector. Annealed product
(1 µl) was used for transformation into NovaBlue cells. Complete protocol for ligation
independent cloning from Novagen is given in Appendix B. Plasmids containing the gene
inserts were extracted using Qiaquick purification protocol and then transformed into E.
coli BL21 (DE3), which was used as protein expression host.
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Figure 3.1. Construction of pET-30 Ek/LIC/ATF-METH expression vector. First, the
gene for ATF-methioninase was amplified by PCR from parental plasmid that inserts 5’
and 3’ LIC ends. Next, the gene was digested with T4 DNA polymerase to create sticky
ends and annealed to linear pET-30 Ek/LIC vector. Finally, annealed product is
transformed in NovaBlue cells.
pKK 223-3/ATF-METH
5’ LIC End 3’ LIC End
PCR
T4 DNA Polymerase
Digestion
pET- 30 Ek/LIC Linear
Vector
pET- 30 Ek/LIC/ATF-
METH Annealed Product
Bacterial transformation of
annealed product into
NovaBlue Cells
ATF-METH
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Component Volume (µl) Stock solution
concentration/amount
Final
concentration/amount
Buffer 10 10 X 1 X
MgCl2 6 25 mM 1.5 mM
dNTP mix 2 10 mM 200 mM (each
dNTP)
5’ Primer 2 15 µM 300 nM
3’ Primer 2 15 µM 300 nM
Template 0.5 ~ 40 ng/µl ~ 20 ng
Polymerase 1 - 3.5 U
dH2O 76 - -
Table 3.1. Reaction composition for PCR.
No. of Cycles Time Temperature oC
1 2 min 94
29 45 s 94
45 s 55
2 min 72
1 5 min 72
1  4
Table 3.2. Cycling parameters for PCR.
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L-Methioninase-Annexin V Fusion Gene
A general outline of the ligation independent cloning scheme for L-methioninase-
annexin (pET-30 Ek/LIC/METHANX) is show in Figure 3.2. The DNA sequences of L-
methioninase and annexin V were amplified using pKK223-3/ATF-METH and pET-
22b(+)/STFANX (obtained from Stuart Lind at the OU Health Sciences Center) as
templates respectively by PCR. Primers were designed to incorporate an LIC sticky end
at the N-terminus and a BamHI restriction enzyme site at the C-terminus end of the L-
methioninase gene. Similarly primers were designed to incorporate a BamHI site at the
N-terminus and a LIC sticky end at the C-terminus of the annexin V gene. Purified PCR
products of L-methioninase and annexin V were treated separately with the BamHI
restriction enzyme in recommended buffer solution. The products from restriction
enzyme digestions were purified using Qiaquick PCR purification kit. Purified products
were ligated together using T4 DNA ligase. This reaction was carried out for 16 h at 4 oC
according to ligase manufacturer recommendations. Ligated product was run on an
agarose gel. The appropriate fragments were cut and agarose gel-purified by the Qiaquick
gel purification kit (see Appendix B). The purified L-methioninase-annexin V gene was
treated with T4 DNA polymerase and annealed to pET-30 Ek/LIC vector as discussed
previously in this section.
TGF-Methioninase Fusion Gene
A general outline of the ligation independent cloning scheme for TGF-
methioninase (pET-44 Ek/LIC/TGF-METH) is show in Figure 3.3. The DNA sequences
of L-methioninase and TGF were amplified using pKK223-3/ATF-METH and
pVC387/TGF as templates respectively by PCR. PCR gene fragments were agarose gel-
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Figure 3.2. Construction of pET-30 Ek/LIC/METHANX expression vector. First, the
genes for L-methioninase and annexin V were amplified by PCR from parental plasmids
that inserts 5’ LIC, 3’ LIC end and BamHI sites. Next, the gene was digested with with
BamHI restriction enzyme and ligated together. The ligated methioninase-annexin gene
was treated with T4 DNA polymerase and annealed to linear pET-30 Ek/LIC vector.
Finally, annealed product is transformed in NovaBlue cells.
pKK 223-3/ATF-METH
PCR
pET- 30 Ek/LIC/ATF-
METH Annealed Product
pET-22b(+)/STFANX
BamHI site 3’ LIC End
PCR
BamHI Digestion/Ligation
5’ LIC End 3’ LIC End
Bacterial transformation of
annealed product into
NovaBlue Cells
5’ LIC End BamHI site
METHANX
METH ANX
T4 DNA Polymerase
Digestion
pET- 30 Ek/LIC Linear
Vector
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Figure 3.3. Construction of pET-44 Ek/LIC/TGFMETH expression vector. First, the
genes for L-methioninase and TGF were amplified by PCR from parental plasmids that
inserts 5’LIC, 3’ LIC end and BamHI sites. Next, the gene was digested with with
BamHI restriction enzyme and ligated together. Ligated TGF-METH gene was treated
with T4 DNA polymerase and annealed to linear pET-44 Ek/LIC vector. Finally,
annealed product is transformed in NovaBlue cells.
T4 DNA Polymerase
DigestionpET- 44 Ek/LIC LinearVector
pET- 44 Ek/LIC/TGF-
METH Annealed Product
Bacterial Transformation
of annealed product into
NovaBlue Cells
BamHI Digestion/Ligation
pKK 223-3/ATF-METH
PCR
BamHI site 3’ LIC End
METH
pVC387/TGF
5’ LIC End BamHI site
PCR
TGF
TGF-METH
5’ LIC End 3’ LIC End
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purified prior to restriction enzyme digestion according to the Qiagen protocol. After
digestion of these gene fragments with BamHI enzyme, they were purified using
Qiaquick PCR purification protocol (See Appendix B). The two fragments were ligated
using T4 DNA ligase. Ligated product was purified according to the Qiaquick agarose gel
purification protocol. The ligated product was annealed to the pET-44 Ek/LIC linear
vector and transformed into NovaBlue cells according to the Novagen protocol. Plasmids
containing the gene inserts were extracted using Qiaquick purification protocol and then
transformed into E. coli BL21 (DE3), which was used as protein expression host.
Annexin V Gene
A general outline of the ligation independent cloning scheme for annexin V (pET-
30 Ek/LIC/ANX) is show in Figure 3.4. The DNA sequence of annexin V was amplified
using pET- 22b(+)/STFANX as template by PCR. The annexin V gene after PCR
reaction was purified by the Qiaquick PCR purification protocol (See Appendix B).
Purified gene was treated with T4 DNA polymerase to create LIC sticky ends on the gene,
and this treated gene was annealed to the pET-30 Ek/LIC linear vector. Annealed product
(1 µl) was used for transformation into NovaBlue cells. Plasmids containing the gene
inserts were extracted using the Qiaquick purification protocol and then transformed into
E. coli BL21 (DE3), which was used as protein expression host.
Site-directed Mutagenesis
A general outline of the site-directed mutagenesis procedure is shown in Figure
3.5. Plasmid containing the ATF-methioninase fusion protein gene (pET-Ek/LIC/ATF-
METH) was mutated by site-directed mutagenesis using PCR. Both of the mutagenic
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Figure 3.4. Construction of pET-30 Ek/LIC/ANX expression vector. First, the gene
for annexin V was amplified by PCR from parental plasmid that inserts 5’ and 3’ LIC
ends. Next, the gene was digested with T4 DNA polymerase to create sticky ends and
annealed to linear pET-30 Ek/LIC vector. Finally, annealed product is transformed in
NovaBlue cells.
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PCR
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Digestion
pET- 30 Ek/LIC Linear
Vector
pET- 30 Ek/LIC/ANX
Annealed Product
Bacterial transformation of
annealed product into
NovaBlue Cells
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40
Figure 3.5. Site directed mutagenesis of pET-30 Ek/LIC/ATF-METH plasmid. First,
PCR was performed using pET-30 Ek/LIC/ATF-METH as plasmid and mutagenic
primers (Y114F, indicated by X). Next, original plasmid was digested by using DpnI
enzyme, and finally the mutated plasmid is transformed in XL1-Blue super competent
cells.
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primers, mMETH 5’ and mMETH 3’ contained the desired mutation at 114th residue of
L-methioninase (Y114F) and anneal to the complimentary sequence on opposite strands
of the plasmid (Appendix A). All the criteria were followed in designing the primers as
discussed in the primer design section. PCR was performed according to Stratagene
protocol (Appendix B). Colonies with the mutation were identified by DNA sequencing,
and plasmid from these colonies was purified and transformed into BL21(DE3) cells,
which was used as protein expression host.
Sequencing Methods
The Oklahoma Medical Research Foundation (OMRF) DNA sequencing facility
used ABI3730 capillary sequencers to sequence all the plasmids containing gene. All the
sequences obtained from the facility were compared with the sequences from GenBank.
This sequencer was able to read sequences up to 600 base pairs. Primers for the
sequencing were designed to have at least 50 base pairs overlapping. The typical size of
the fusion protein gene is around 1350 base pairs, so three primers were used to read
entire sequence. The first primer was designed to have an overlap region with the vector,
and the last primer was made sure to read the sequence on the 3’ end of the vector. The
primers sequences used are given in Appendix A.
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Protein Expression
A culture of E. coli BL21(DE3) haboring pET- 30 Ek/LIC with the fusion gene of
interest (ATF-methioninase, mutated ATF-methioninase, L-methioninase, methioninase-
annexin V or annexin V) was grown in 50 ml of LB medium containing 35 µg/ml
kanamycin overnight at 37 oC with shaking. This cell culture was added to 1 liter of fresh
culture medium, and the culture was grown with shaking at 37 oC. This cell culture was
grown to mid-log phase (OD600 = 0.5) and protein expression was induced by adding
isopropyl -D-thiogalactopyranoside (IPTG) to a final concentration of 0.4 mM. After
addition of IPTG, the shaking of cell culture was continued at 30 oC for 5 h and harvested
by centrifugation for 10 min at 1000 x g. For the expression of TGF-methioninase using
plasmid pET-44 Ek/LIC, the same procedures were used, except ampicillin at 100 µg/ml
was used instead of kanamycin for the cell culture and protein expression was induced
using 1 mM IPTG for 3 h at 37 oC. The cell pellet was resuspended in 40 ml of sonication
buffer containing 0.05 mM N- p-tosyl-L-phenylalanine chloromethyl ketone (TPCK), 1
mM phenylmethylsulfonyl fluoride (PMSF), 1% ethanol, 0.02 mM pyridoxal phosphate,
0.01% -mercaptoethanol and 0.02 M sodium phosphate at pH 7.4. The sonication buffer
used for cell pellet containing annexin V contains 0.05 mM TPCK, 1 mM PMSF, and
0.02 M sodium phosphate at pH 7.4. The cells were lysed by sonication at 4 oC for 30
sec at 4.5 watts per ml of lysate and then allowed to cool for 30 sec on ice. This cycle was
repeated for four times for a total sonication time of 2.5 min. The lysate obtained was
centrifuged at 12,000 x g for 30 min to remove the cell debris.
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Protein Purification
All the fusion proteins expressed using a pET-30 Ek/LIC vector have an N-
terminal His-tag (His6) sequence with an integrated thrombin (Thr) cleavage site,
enterokinase (Ek) cleavage site, and an engineered HRV 3C protease site next to the start
of the fusion protein (His6/Thr/Ek/3C/Fusion protein). The TGF-methioninase expressed
using pET-44 Ek/LIC has an N-terminal His-tag sequence with an integrated NusA-tag,
Ek cleavage site, and an engineered HRV 3C protease site next to the start of fusion
protein (His6/NusA/Ek/3C/TGF-methioninase). All the purification steps are performed
at 4 oC. The entire purification procedure is outlined in Figure 3.6. Imidazole (40 mM)
and NaCl (500 mM) were added to the lysate to reduce non-specific protein binding. This
resulting mixture was fed to 5 ml HisTrap chromatography column with immobilized
Ni2+, which was equilibrated with wash buffer containing 20 mM sodium phosphate, 40
mM imidazole, 500 mM NaCl, 0.02 mM pyridoxal phosphate (not added for annexin V
expression) at pH 7.4. The column was washed with the wash buffer to remove unwanted
proteins. His-tagged fusion protein was eluted using elution buffer containing 20 mM
sodium phosphate, 500 mM imidazole, 500 mM NaCl, and 0.02 mM pyridoxal phosphate
at pH 7.4. Eluted protein was dialyzed overnight against buffer containing 20 mM
sodium phosphate, 0.02 mM pyridoxal phosphate at pH 7.4 to remove NaCl and
imidazole from the protein solution and make suitable for N-terminal His-tag cleavage.
Buffers used for purification of annexin V do not contain pyridoxal phosphate. The
cleavage of N-terminal His-tag was achieved by using HRV 3C protease. HRV 3C
protease (0.5 Units/mg of protein) and recommended 10X buffer (1.5 M NaCl, 0.5 M
Tris-HCl, pH 7.5) were added to protein solution. This reaction was carried out for 8 h at
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Figure 3.6. Scheme for the purification of fusion proteins using immobilized metal
affinity chromatography.
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4 oC. Imidazole (40 mM) and NaCl (500 mM) were added to the cleaved protein solution,
which was fed again onto a 5 ml HisTrap column. Pure protein was eluted in a linear
gradient of 0-0.5 M imidazole. Purified protein was dialyzed overnight against 20 mM
sodium phosphate buffer at pH 7.4 containing 0.02 mM pyridoxal phosphate and 0.1 M
NaCl.
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Freeze Drying / Lyophilization.
Purified protein obtained after chromatography was concentrated to the desired
concentration using Centriprep centrifugal filters. Concentrated protein solution was then
transferred to small 1.5 mL centrifuge tubes. A small pinhole was introduced on the cap
of each tube to let vapors escape. These tubes were flash frozen using liquid nitrogen and
transferred in 20 mL lyophilization vials holding 10-15 centrifuge tubes. Lyophilization
vials were then loaded onto the freeze dryer for lyophilization. Typically, lyophilization
was carried out for 8 h.
Methioninase Activity Assay
The enzymatic activity of L-methioninase was determined by measuring the
absorbance of azine derivatives formed by reacting 3-methyl-2-benzothiazolone
hydrazone hydrochloride and -ketobutyrate [98]. -ketobutyrate was the product
obtained by enzymatic elimination of L-methionine by L-methioninase (Appendix B).
SDS-PAGE, Western blotting, and Protein Assays
Cellular proteins and proteins after purification were separated on 12 % (w/v)
SDS-PAGE and stained with Coomassie brilliant blue (see Appendix B). Protein
concentration was measured by the Bradford assay (Bio-Rad, see Appendix B). The
complete protocol for the Western blotting is given in Appendix B. Densitometry
scanning of SDS-PAGE gels was carried out using Quantity One software (Bio-Rad).
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Amino-terminal Sequencing
Protein sequencing was performed on an Applied Biosystems Procise model 492-protein
sequencer equipped with an on-line PTH-amino acid analyzer and model 610A data
system by the Molecular Biology Resource Facility at the University of Oklahoma Health
Sciences Center. This protein sequencing was done only on the ATF-methioninase fusion
protein, and results obtained from the facility were compared with the available protein
sequence. This method was also used to determine the purity of the given sample.
Culture Wounding Assay
Cancer cells (5.0 x 105) were seeded into 60 mm culture dishes in 3 ml of RPMI
medium. Three days after seeding, at approximately 80 % confluency, the cell cultures
were wounded. The wound was created by pressing the edge of a razor blade, placed in a
blade holder, into the confluent monolayer. The blade created a distinct mark on the
culture dish. While holding the razor firmly, a rubber policeman was used to gently
scrape away cells on one side of the razor blade creating a wounded area. The culture was
then washed twice with PBS, and the wounded area carefully examined under the
microscope to verify that the wound was completely cell free as previously described
[95].
The wounded culture was treated with media containing either various
concentrations of the fusion proteins or L-methioninase. In each experiment control
cultures received RPMI media alone. At 24, 48 and 72 hours following treatment, cell
migration and proliferation were determined by measuring both the maximum distance
traveled by the cell front into the wounded area (migration) and number of cells in the
wounded area (proliferation)/microscopic field. Measurements were taken from 10-12
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individual microscopic fields in each experiment, and data was summarized from 2-3
experiments. Wounded cultures were examined at 100X magnification under an inverted
phase-contrast microscope equipped with grid-containing eyepiece.
Mouse Xenograft Assay
In this study, MCF-7 human breast cancer cells (106) suspended in 0.2 ml
Matrigel were injected into the flank of nude mice as previously described [95]. A pellet
of estradiol (100 µg) was placed adjacent to the gel implantation site 48 h prior to cell
implantation. These cells are stably transfected with the -galactosidase (-gal) reporter
gene so that tumor metastasis could be determined and quantified. The longest
perpendicular diameters of tumors were measured twice weekly to document tumor
growth. Tumor measurements were converted to tumor volume (V) using the formula: V
= W2 x Y/2, where W and Y are the smaller and larger perpendicular diameters,
respectively. The body weight of mice was also measured twice weekly. The
development of tumor masses was monitored over a period of 30 days. The animals were
then randomly placed into treatment groups containing 10 animals per group. Treatment
groups received either the fusion protein (each treated with 25 µl/day of 10-6, 10-7, or 10-8
M fusion protein or L-methioninase or vehicle in the control group by intra-tumoral
injection on alternate days (see Appendix B). The animals were treated for period of 20
days. At the end of the treatment period, the animals were euthanized. Cancer cells in the
tumor tissue were quantified by colorimetric measurement of the -gal reporter in each
sample.
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Measurement Using the Colorimetric Substrate, Chlorophenol Red -D-
Galactopyranoside (CPRG)
Fresh tissue samples were collected from tumors, lung, and liver of nude mice.
These samples were analyzed for number of cancer cells by measuring endogenous -gal
activity as previously described [95]. Samples were flash frozen using liquid nitrogen and
ground. Then the samples were resuspended in lysis buffer (50 mM HEPES, 5 mM
CHAPS, pH 7.5). The tissue samples were lysed by sonication at 4 oC for 30 sec at 4.5
watts per ml of lysate and then allowed to cool for 30 sec on ice. This cycle was repeated
for four times for a total sonication time of 2.5 min. The lysate obtained was centrifuged
at 12,000 x g for 30 min to remove the cell debris. The CPRG assay was performed on
the tissue samples collected as outlined in the protocol provided with the kit (See
Appendix B). A standard curve of absorbance versus cell number was generated by blank
MCF-7 cells, which were transfected by the -gal reporter gene.
Binding of Methioninase-Annexin V on Plastic-immobilized Phosphatidylserine
Phosphotidylserine (PS) was dissolved in chloroform at a concentration of 50
µl/ml. This solution (100 µl) added to wells of a 96-well polypropylene microtiter plates.
This plate was allowed stay in a laminar flow hood until all the chloroform was
evaporated. The plate was then blocked/washed by using wash/dilution buffer (phosphate
buffered saline (PBS) solution containing 10% fetal bovine serum at pH 7.0 and 2 mM
calcium chloride) for 2 h at room temperature in the laminar flow hood. Methioninase-
annexin V fusion protein was added to wash buffer at an initial concentration of 6.7 nM.
Serial 2-fold dilutions of this concentrated fusion protein were done using dilution buffer
to give a final concentration of 6.7 pM. Methioninase-annexin V was added to wells in
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the increasing concentration of methioninase-annexin V. For each concentration of
methioninase-annexin V, the experiment was done in triplets. After adding 100 µl of
methioninase-annexin V, the plates were incubated for 2 h. The plates were washed with
wash buffer, and primary antibody (rabbit anti-methioninase) diluted in wash buffer
(1:1000) was added and incubated for 12 h at 4 oC. The plates are again washed with
wash buffer, and 100 µl of goat anti-rabbit IgG secondary antibody with HRP conjugated
(1:1000 dilution in binding buffer) was added to the wells for 2 h at room temperature.
The chromogenic substrate O-phenylenediamine (OPD, 200 µl) was used to detect the
HRP by reading the plates at 450 nm. Further details of this procedure are given in
Appendix B.
Binding of Methioininase-Annexin V on Externally Positioned PS on the Surface of Cells
MCF-7 breast cancer cells were grown using DMEM media containing 10% FBS
until they reached 85 % confluence in T-75 flasks. Cancer cells (5 x 104) were transferred
to 24 well plates and grown until they reached 85 % confluence. PS was exposed on the
surface of cells by the addition of hydrogen peroxide (1 mM). Cells were treated with
wash/binding buffer containing the DMEM media with 1 mM of H2O2 for 1 h at 37 oC.
Cells were fixed with 0.25 % glutaraldehyde diluted in PBS buffer containing Ca2+ (2
mM). Excess aldehyde groups were quenched by incubation with 50 mM of NH4Cl for 5
min. Methioninase-annexin V fusion protein was added to wash buffer at an initial
concentration of 6.7 nM. Serial 2-fold dilutions of this concentrated fusion protein
solution were done to give a final concentration of 6.7 pM. Methioninase-annexin V was
added to wells in the increasing concentration of methioninase-annexin V. For each
concentration of methioninase-annexin, the experiment was done in triplets. After adding
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300 µl of methioninase-annexin V, the plates were incubated for 2 h. The plates were
washed with wash buffer, and primary antibody (rabbit anti-methioninase) diluted in
wash buffer (1:1000) was added and incubated for 12 h at 4 oC. The plates are again
washed with wash buffer, and 300 µl of goat anti-rabbit IgG secondary antibody with
HRP conjugated (1:1000 dilution in binding buffer) was added to the wells for 2 h at
room temperature. After washing with PBS, the chromogenic substrate O-
phenylenediamine (OPD, 300 µl) was added. After 30 min 100 µl of the supernatant was
transferred to 96-well plates, and absorbance was measured at 450 nm. Further details of
this procedure are given in Appendix B.
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4. RESULTS AND DISCUSSION
Construction of Fusion Genes
Construction of the ATF-Methioninase Fusion Gene and the L-Methioninase Gene
Figure 4.1.A presents the results of the PCR reactions using pKK223-3/ATF-
METH as template and primers for the ATF-methioninase fusion gene, and the L-
methioninase gene, as visualized by agarose gel electrophoresis. Visualization of PCR
fragments of correct lengths (1452 base pairs for the ATF-methioninase gene and 1284
base pairs for the L-methioninase gene) provided confirmation that the gene fragments
were indeed the desired synthesis products. Only a fraction of the PCR product (5% of
the total) was used to visualize by agarose gel electrophoresis, and the rest was purified
using Qiaquick PCR purification protocol (Appendix B). Purified product was treated
with T4 DNA polymerase, and the treated gene was annealed to linear pET-30 Ek/LIC
vector. After transformation of the annealed product into E. coli NovaBlue Giga Singles,
five colonies were picked and cultured. Plasmids were extracted using Qiaquick plasmid
purification protocol (See Appendix B) from these cultures and sent for DNA sequencing.
Four out of five colonies were shown to have the ATF-methioninase fusion gene inserted,
and one of colonies showed self-ligation of the vector. This self-ligation of the vector is
attributed to degradation of the linear vector during handling. For the L-methioninase
gene as insert, all the five colonies picked showed the gene to be inserted. The consensus
DNA sequence resulting from the sequencing of the pET-30 Ek/LIC/ATF-METH and
pET-30 Ek/LIC/METH vectors is shown in Appendix A.
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A B C
Figure 4.1. (A) Agarose gel image of PCR products. Lane 1, ATF-methioninase (1452
bp) fusion gene, and Lane 2, L-methioninase gene (1284 bp). (B) Agarose gel image of
PCR products. Lane 1, different ligated products formed after ligation reaction of L-
methioninase and TGF. TGF-METH is indicated by arrow. Lane2, L-methioninase (1284
bp); Lane3, TGF (214 bp), and (C) Agarose gel image of PCR products. Lane1, Annexin
V, Lane2, L-methioninase; and Lane 3, different ligated products formed after ligation
reaction of L-methioninase (1284 bp) and annexin V (1013 bp). Lane M, the 1 kb DNA
ladder ( 0.5 kb, 1 kb, 1.5 kb, 2.0 kb, 3 kb, 4 kb).
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Construction of TGF-Methioninase Fusion Gene
Figure 4.1.B presents the result of the PCR reaction using pKK223-3/ATF-
METH as template for the L-methioninase gene (lane 2) and the result of the PCR
reaction using pVC387/TGF as template for the TGF gene (lane 3), as visualized by
agarose gel electrophoresis. Visualization of PCR fragments of correct lengths (1284 base
pairs for the L-methioninase gene and 165 base pairs for the TGF gene) provided
confirmation that the gene fragments were indeed the desired synthesis products. The L-
methioninase and TGF genes are treated with BamHI restriction enzyme at 37 oC for 1 h.
These two genes were ligated using T4 DNA ligase at room temperature for 3 h. Lane 1
of Figure 4.1.B presents the result for the ligation reaction, as visualized by agarose gel
electrophoresis. Five bands are visualized corresponding to different ligated products: 1)
L-methioninase gene ligated to itself (~2548 bp), 2) L-methioninase gene ligated to the
TGF gene (a 1438 base pairs gene as shown in Figure 4.1.B by an arrow), 3) unligated L-
methioninase gene (1284 bp), 4) TGF gene ligated to itself (~ 326 bp), and 5) 165 base
pair unligated TGF gene. The band corresponding to the TGF-methoninase gene was
excised from agarose gel and purified using the Qiaquick agarose gel purification
protocol (see Appendix B). Purified product was treated with T4 DNA polymerase and
annealed onto the linear pET-44 Ek/LIC vector. After transformation of annealed product
into E. coli NovaBlue Giga Singles, five colonies were picked and cultured. Plasmids
were extracted using the Qiaquick Plasmid purification protocol (see Appendix B) from
these cultures and sequenced. The consensus DNA sequence resulting form the sequence
of the pET-44 Ek/LIC/TGF-METH is shown in Appendix A.
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Construction of the L-Methioninase-Annexin Gene
Figure 4.1.C presents the result of the PCR reaction using pKK223-3/ATF-
METH as template for the L-methioninase gene (lane 2), and the result for the PCR
reaction using pET-22b(+)/STF-ANX as template for the annexin V gene (lane 3), as
visualized by agarose gel electrophoresis. Visualization of PCR fragments of correct
lengths (1284 base pairs for the L-methioninase gene and 1013 base pairs for the annexin
V gene) provided confirmation that the gene fragments were indeed the desired synthesis
products. The L-methioninase and annexin V genes are treated with BamHI restriction
enzyme at 37 oC for 1 h. These two genes were ligated using T4 DNA ligase at room
temperature for 3 h. Lane 1 of Figure 4.1.C presents the result for the ligation reaction,
as visualized by agarose gel electrophoresis. Five bands are visualized corresponding to
different ligated products: 1) L-methioninase gene ligated to itself (~2548 bp), 2) L-
methioninase gene ligated to annexin V gene (a 2297 base pairs gene as shown in Figure
4.1.C by an arrow), 3) unligated L-methioninase gene, 4) annexin V gene ligated to itself
(~ 2026 bp), and 5) 1013 base pair unligated annexin V gene. The band corresponding to
the L-methioninase–annexin V gene was excised from the agarose gel and purified using
the Qiaquick agarose gel purification protocol (see Appendix B). The purified product
was treated with T4 DNA polymerase and annealed to the linear pET-30 Ek/LIC vector.
After transformation of annealed product into E. coli NovaBlue Giga Singles, five
colonies were picked and cultured. Plasmids were extracted using Qiaquick plasmid
purification protocol (See Appendix B) from these cultures and sent for DNA sequencing.
The consensus DNA sequence resulting from the sequencing of the pET-30 Ek/LIC/L-
METHANX is shown in Appendix A.
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On a whole, the efficiency of LIC is much greater than for conventional cloning. Both the
linearized vector and the PCR product containing the gene to be cloned are treated with
T4 DNA polymerase in the presence of a single dNTP to generate complementary
overhangs, which are unique for each end of the gene. Therefore, it is impossible for the
vector to anneal to itself with no insert, which commonly occurs in conventional cloning.
The 3’-endonuclease activity of the polymerase removes bases from the 3’-end of each
duplex DNA until it encounters the nucleotide matching the single added dNTP. At that
point, polymerase activity dominates, stopping the endonuclease activity and leaving a 5’
single-stranded overhang.
Site Directed Mutagenesis of pET- 30 Ek/LIC/ATF-METH
PCR was performed on pET-30 Ek/LIC/ATF-METH, and after DpnI enzyme
digestion of the PCR products, 1 µl of the PCR product was used for the transformation
into E. coli XL1-Blue. Many colonies were picked and cultured. Plasmid was extracted
from these colonies and sequenced. Two out of ten colonies picked showed the point
mutation (Y114F). The entire gene was sequenced to check for any mutations caused by
the PCR. Using this method for creating site directed mutations was easy, but the DpnI
enzyme digestion of the template plasmid was critical.
Protein Expression and Purification
Plasmids containing the gene inserts were extracted using the Qiaquick
purification protocol and then transformed into E. coli BL21 (DE3). Expression of ATF-
METH fusion protein using 1 mM IPTG at 37 oC for 3 h, or using 0.4 mM IPTG at 37 oC
for 3 h resulted in completely insoluble fusion protein based on SDS-PAGE gels.
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Expression of fusion protein using 0.4 mM IPTG at 30 oC for 6 h resulted in soluble
fusion protein. Expression for 6 h at 30 oC was used for all the proteins except for TGF-
METH fusion protein. TGF-METH fusion protein was expressed using 1 mM IPTG for 3
h at 37 oC. This produced a soluble fusion protein with a NusA tag attached at the N-
terminal of the TGF-METH.
Purification of all the fusion proteins was done by immobilized metal affinity
chromatography using a Ni2+ column. L-methioninase, ATF-methioninase, mutated ATF-
methioninase, annexin V, and methioninase-annexin V all had an integrated His6 tag,
thrombin cleavage site, enterokinase site and engineered HRV 3C protease site next to
the start of fusion protein (His6/Thr/Ek/3C/Fusion protein). The TGF-methioninase fusion
protein had a NusA tag next to thrombin cleavage site (His6/NusA/Thr/Ek/3C Fusion
protein).
Figure 4.2 is the SDS-PAGE gel image showing the purification of ATF-
methioninase fusion protein at different stages. The concentrations of 40 mM of
imidazole and 500 mM of NaCl were chosen for the wash buffer and elution buffer,
respectively, to reduce the non specific binding of the unwanted proteins. Use of this
concentration of imidazole has resulted in some loss of fusion protein in wash, but the
protein obtained in elution pool was pure. Following this IMAC purification, the pure
fusion protein was dialyzed against HRV 3C enzyme buffer. The reason for engineering
HRV 3C protease next to fusion protein is because of previous experience of using
bovine enterokinase to cleave the His6 tag from the fusion proteins. For fusion proteins
with no HRV 3C site, use of enterokinase to cleave the His6 tag resulted in incomplete
cleavage. Cleaved protein bound to un-cleaved protein (since L-methioninase exists as
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Figure 4.2. SDS-PAGE analysis with Coomassie blue staining of the expression and
purification of the ATF-methioninase fusion protein (position indicated by the arrow).
The fusion protein was expressed from plasmid pET-30/Ek/LIC/ATF-Meth in E. coli
BL21(DE3) cells at 30 ºC (lane 1 whole cells, lane 2 soluble lysate, lane 3 eluted
fraction from first metal affinity chromatography, lane 4 eluted fraction after cleavage
with HRV 3C protease, lane 5 pooled fractions from second metal affinity
chromatography, M marker proteins with molecular masses indicated on the left in
kiloDaltons).
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tetramer in native state), and this resulted in a low yield of purified product after
purification. Use of HRV 3C protease resulted in complete cleavage of protein and did
not give non-specific cleavage of fusion proteins. However, use of HRV 3C protease left
an N-terminal Gly-Pro on the target protein. HRV 3C protease has a His6 tag, and it was
easily removed by IMAC. Use of thrombin was not a choice because it was positioned
next to enterokinase site. Following HRV 3C protease cleavage of the fusion protein, it
was fed onto a HisTrap column again, and usually the target protein was collected in the
start of the elution gradient of 0-0.5 M imidazole. This could be due to the non-specific
binding of the ATF-methioninase fusion protein to the column. A similar procedure was
used purify the L-methioninase, mutated ATF-methioninase, annexin V, and
methioninase-annexin V fusion proteins. Figure 4.3 is the SDS-PAGE gel image
showing the purification of L-methioninase protein at different stages of purification. The
SDS-PAGE gel image showing the purification of mutated ATF-methioninase is not
shown, but it is similar to Figure 4.2.
Figure 4.4 is the SDS-PAGE gel image showing the purification of TGF-
methioninase fusion protein at different stages of purification. The procedure used to
purify TGF-methioninase is similar to that of ATF-methioninase. Lane 4 in the Figure
4.4 corresponds to the pooled fractions from the second metal affinity chromatography,
and lane 5 corresponds to eluted fraction from second metal affinity chromatography.
Although there was nearly complete cleavage of NusA and TGF-methioninase by HRV
3C protease as shown in lane 3 of Figure 4.4, TGF-methioninase and the protein with the
NusA tag eluted together for some of the fractions (see lane 5). Since L-methioninase is a
homotetramer, incomplete cleavage can result in noncleaved protein binding up to three
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Figure 4.3. SDS-PAGE analysis with Coomassie blue staining of the expression and
purification of the L-methioninase protein (position indicated by the arrow). The fusion
protein was expressed from plasmid pET-30/Ek/LIC/METH in E. coli BL21(DE3) cells
at 30 ºC (lane 1 soluble lysate, lane 2 eluted fraction from first metal affinity
chromatography, lane 3 eluted fraction after cleavage with HRV 3C protease, lane 4
pooled fractions from second metal affinity chromatography, M marker proteins with
molecular masses indicated on the left in kiloDaltons).
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Figure 4.4. SDS-PAGE analysis with Coomassie blue staining of the expression and
purification of the TGF-methioninase fusion protein (position indicated by the arrow).
The fusion protein was expressed from plasmid pET-44/Ek/LIC/TGF-METH in E. coli
BL21(DE3) cells at 30 ºC (lane 1 soluble lysate, lane 2 eluted fraction from first metal
affinity chromatography, lane 3 eluted fraction after cleavage with HRV 3C protease,
lane 4 pooled fractions from second metal affinity chromatography, lane 5 eluted fraction
from second metal affinity chromatography, M marker proteins with molecular masses
indicated on the left in kiloDaltons).
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cleaved protein fragments to give a complex that will have a His6 tag and will bind to the
column more strongly than a complex that was completely cleaved. If, for example, the
cleavage was 90% complete, half of the cleaved TGF-methioninase would elute with the
His6 tag because of the association of the L-methioninase monomers. This contributed to
a lower yield for TGF-methioninase than for the other fusion proteins (Table 4.1).
Figure 4.5 is the SDS-PAGE gel image showing the purified protein products of
annexin V, L-methioninase, and methioninase-annexin V. The yield and specific activity
of the fusion proteins are shown in Table 4.1. There was a relatively high yield of
purified proteins expressed using pET-30 Ek/LIC vector. The yield of TGF-methioninase,
expressed using the pET-44 Ek/LIC vector, was 4-6 fold lower than for the proteins
expressed by the pET-30 Ek/LIC vector. The specific activity of methioninase-annexin V
was lower when compared to L-methioninase and ATF-methioninase as expected. This is
due to fusion of the 36 kDa annexin V protein to L-methioninase when compared to the 5
kDa proteins ATF or TGF.
The purity of the ATF-methioninase fusion protein was estimated to be 94% using
Quantity One densitometry software analysis of lane 5 of the SDS-PAGE gel in Figure
4.2. Amino acid sequencing of the purified ATF-methioninase fusion protein was
performed on the first eight amino-terminal amino acids. The sequence was identical to
the amino-terminus of the urokinase A chain (Gly-Pro-Ser-Asn-Glu-Leu-His-Gln) for 90
± 5% of the protein, which is consistent with the purity estimation of the SDS-PAGE gel
of the purified protein. The purity of the TGF-methioninase fusion protein was estimated
to be 97 % using the densitometry software analysis of lane 4 of SDS-PAGE gel in
Figure 4.4. Amino acid sequencing of the TGF-methioninase fusion protein was
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Protein Amino
Acids
Theoretical
Molecular
Weight
(kDa)
Runs Yield
(mg/liter of
culture)
Specific
Activity
(Units/mg)
L-methioninase 399 42.75 2 65.3 14.6
ATF-
methioninase
455 48.64 2 53.5 13.9
Mutated ATF-
methioninase
455 48.64 1 55.4 0
Methioninase-
annexin V
729 79.62 1 41.3 8.6
Annexin V 321 35.92 1 59.2 0
TGF-
methioninase
457 48.87 1 11.3 12.5
Table 4.1. Average yield and specific activity of purified fusion proteins.
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Figure 4.5. SDS-PAGE analysis with Coomassie blue staining of three of the purified
proteins. Lane 1 annexin V, lane 2 L-methioninase, lane 3 methioninase-annexin V, M
marker proteins with molecular masses indicated on the left in kiloDaltons.
Figure 4.6. Western blot analysis of ATF-methioninase and L-methioninase proteins.
Lane 1, ATF-methioninases; lane 2, L-methioninase.
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performed on the amino-terminus. and the result obtained showed that 65% of sequence
was identical to the amino terminal sequence of the TGF- which is not consistent with
the purity estimated by SDS-PAGE gel. The impurity sequence was not from the protein
tag cleaved off or from TGF-.
Dimer Formation of ATF-Methioninase and L-Methioninase
Western blot analysis shown by the Figure 4.6 confirms that the ATF-
methioninase and L-methioninase were not completely reduced to a monomeric state in
an SDS-PAGE gel. An increase of the concentration of -mercaptoethanol (BME) or the
use of a stronger reducing agent, dithiothreitol (DTT), was not effective in reducing these
proteins. After using newly purchased DTT and BME, the dimer formations were greatly
reduced, but not completely eliminated.
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Freezing and Freeze Drying
Figure 4.7 summarizes the effect of freezing on the ATF-methioninase fusion
protein. Freezing of the fusion protein proved to be detrimental to the protein activity.
This could be due to complex physical and chemical changes caused by freeze-thaw
cycles. In an initial attempt, slow freezing of the protein was tried, by placing the sample
in the -20 oC freezer, and it resulted in a loss of 67 % of the activity. This activity loss
was reduced to 31 % by flash freezing in liquid nitrogen (-170 oC). One main possible
reason for substantial loss of activity during slow freezing is that, as water crystallizes out,
the remaining solutes are concentrated with the proteins, which might cause the phase
separation of some solutes due to their low solubility limit; this concentration of solutes
may not dissipate immediately during thawing, leading to the protein instability [99, 100].
Selective crystallization of disodium phosphate upon freezing has been reported earlier
[101]. Also surface denaturation at the ice-water interface was also reported earlier [102].
However, during flash freezing of the fusion protein, relatively smaller crystals are
formed, and therefore there was a relatively equal distribution of proteins and solutes in
the frozen liquid. Although the loss of activity of fusion protein during flash freezing was
reduced when compared to the loss of activity during slow freezing of fusion protein,
there was a significant loss of activity (31 %) during this unit operation. This loss was
probably due to the increase in surface area by formation of smaller ice crystals,
eventually increasing the protein-ice interaction and causing the denaturation of fusion
protein. Addition of salt (NaCl 100 mM) resulted in 94% of the activity being retained
after flash freezing and 87% of activity retained after flash freezing followed by freeze
drying. This higher yield of activity is believed to be caused by a reduction in the
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Figure 4.7. Effect of different unit operations on specific activity of ATF-methioninase.
MAC 1: First Metal Affinity Chromatography, MAC 2: Second Metal Affinity
Chromatography. Each bar corresponds to the specific activity of the fusion at different
purification stage and also freezing.
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interaction between protein and ice crystals [100]. Similar effects of freezing were
observed on all the fusion proteins containing L-methioninase.
Inhibitory effects of ATF-methioninase on Cancer Cells In Vitro
In control experiments for the culture wounding assay, MCF-7 cancer cells were
treated with buffer 1 (20 mM sodium phosphate, 0.02 mM pyridoxal phosphate, 1mM
ethylene diamine tetra-acetic acid (EDTA), 1 % ethanol, and 1 mM PMSF, NaCl), and
also with the buffer 2 (20 mM sodium phosphate, 0.02 mM pyridoxal phosphate and 0.02
% BME). These two buffers were used to dissolve the proteins before administration. It
was observed that this buffer 2 produced a significant, but very small cytotoxicity to the
MCF-7 cancer cells when compared to buffer 2 (Figure 4.8). Based on this result, the
proteins were dissolved in buffer 1 before the administration to the cells or mouse
xenografts.
The cell migration and proliferation indices of MCF-7 breast cancer cells were
significantly reduced in methionine-free media containing homocysteine, verifying that
these cells are methionine-dependent [93]. In the culture wounding experiments, ATF-
methioninase over the concentration range of 10-8 M to 10-6 M produced a dose-related
inhibition of cell migration and proliferation for MCF-7 breast cancer cells on days 2 and
3 (p<0.05, Figure 4.9). Mutated ATF-methioninase did not inhibit cell migration or
proliferation over the same concentration range. L-methioninase produced a smaller but
significant (p<0.05) reduction in migration and proliferation on days 2 and 3 [95].
The effects of ATF-methioninase on SK-LU-1 lung cancer cells were examined
over a concentration range of 10-8 to 10-6 M as shown in Figure 4.10. In these
experiments, the fusion protein consistently produced a dose-related inhibition of both the
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Figure 4.8. Effect of buffers on MCF-7 breast cancer cell migration and proliferation.
Control, cells treated with RPMI media alone; Buffer 1, cells treated with RPMI media
and buffer containing 20 mM sodium phosphate, 0.02 mM pyridoxal phosphate 1 mM
EDTA, 1 mM PMSF, and 1 % ethanol; Buffer 2, Cells treated with RPMI media and
buffer containing 20 mM sodium phosphate, 0.02 mM pyridoxal phosphate and 0.02 %
BME.
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Figure 4.10. Dose-response effect of fusion protein on SK-LU-1 lung cancer cells on
proliferation and migration. ATF-methioninase (FP); mutated ATF-methioninase (M-FP);
L-methioninase (L-M) were administered immediately following culture wounding.
Each bar in the top panel represents the number of cells that migrated into the wounded
area (mean ± SEM from 10 to 12 microscope fields). Each bar in the bottom pannel
represents number of viable cells in the wounded area (mean± SEM from 10 to 12
microscope fields).
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proliferation and migration of the lung cancer cells on days 2 and 3 following fusion
protein treatment at all concentrations (p<0.05) [96]. The fusion protein with a mutated
L-methioninase produced little or no inhibition of cell proliferation or migration over the
same concentration range. Treatment of SK-LU-1 cancer cells with L-methioninase alone
produced a significant inhibition (p<0.05) of cell migration on days 2 and 3 following
treatment only at the highest concentration of 10-6 M, and proliferation was significantly
inhibited (p<0.05) on day 2 only at 10-6 M but was not inhibited on day 3 at any of the
concentrations. Thus, L-methioninase induced inhibition was much smaller than that
produced by the fusion protein.
The effects of ATF-methioninase fusion protein on PC-3 prostate cancer cells
were examined over a concentration range of 10-6 to 10-8 M as shown in Figure 4.11. In
these experiments, the fusion protein consistently produced a dose-related inhibition of
both the proliferation and migration of the cancer cells on days 2 and 3 following fusion
protein treatment at all concentrations (p<0.05) [96]. The fusion protein with a mutated
L-methioninase again produced little or no cell proliferation or migration over the same
concentration range. Treatment of the PC-3 cancer cells with L-methioninase alone
consistently produced a significant reduction in proliferation and migration on all three
days only at the highest concentration of 10-6 M (p<0.05). The L-methioninase-induced
inhibition was significantly less than that produced by the fusion protein on day 3 at all
concentrations tested (p<0.05).
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Figure 4.11. Dose-response effect of fusion protein on PC-3 prostate cancer cells on
proliferation and migration. ATF-methioninase (FP); mutated ATF-methioninase (M-FP);
L-methioninase (L-M) were administered immediately following culture wounding.
Each bar in the top panel represents the number of cells that migrated into the wounded
area (mean ± SEM from 10 to 12 microscope fields). Each bar in the bottom pannel
represents number of viable cells in the wounded area (mean± SEM from 10 to 12
microscope fields).
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Specific peptide-based inhibitors of the uPAR were developed where the peptide
blocks the uPAR interactions and reduce the progression of the human breast cancer [103,
104]. For example, maspin, a serine protease was found to inhibit tumor growth in vivo
[105]. Another example, the antagonists of uPA binding to uPAR has been developed
based on the binding region of the growth factor domain of uPA. These peptides were
successfully used to inhibit the binding of uPA to uPAR [106, 107]. Fusion protein
uPA/IgG was found to be useful antagonist to uPAR which inhibited the metastasis of
PC3 prostate cancer cells, human melanoma, colon cancer, and head and neck cancer
cells [63, 108]. Although in this fusion protein uPA containing 135 amino acids was used,
this was believed to have stronger binding affinity to uPAR.
As expected synergistic inhibitive effect of ATF-methioninase as antagonist to the
uPAR receptor and methioninase activity was not found in either of these experiments.
This can be seen by the lack of inhibition with the mutated ATF-methioninase which
implied that cytotoxicity is only caused by L-methioninase which is targeted to the cell
surface. Inactivation of urokinase receptor on cancer cell surface by mutated ATF-
methioninase at a concentration of 10 -6 M (Figure 4.8, Figure 4.9, and Figure 4.10) had
no effect on cancer cell proliferation and migration which suggested that the
concentrations of mutated ATF-methioninase used were not sufficient to saturate the
urokinase receptors on the cancer cell surface to prevent the signaling cascade caused by
binding of ATF. Use of mutated ATF-methioninase as an antagonist to urokinase was not
studied in this project.
The inhibitive effect on cell proliferation produced by ATF-methioninase for the
concentration of 10-6 M is higher for MCF-7 breast cancer cells than for PC-3 prostate
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cancer cells or SK-LU-1 lung cancer cells. Cancer cells have varying degrees of
methionine dependence, and it is therefore, likely that the MCF-7 cancer cells have a
greater degree of methionine dependence than the SK-LU-1 or PC-3 cancer cells.
Daily Admistration of ATF-Methioninase
In this experiment, culture plates received a fresh batch of ATF-methioninase
fusion proteins after every 24 h for 3 days. Each day the media was removed and refilled
with the media containing the fusion protein at the desired concentration. There was no
significant difference in inhibition of cell proliferation and migration after 3 days for the
plates which received fusion proteins daily compared to single administration of fusion
protein as shown in Figure 4.12.
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Figure 4.12. Effect of daily administration of ATF-methioninase fusion protein (FP) to
the MCF-7 cancer cells.
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
Control FP 10-6M FP 10-7M FP 10-6M/day FP 10-7M/day
Treatments
Ce
ll
fr
o
n
td
is
ta
n
ce
(m
m
)
1 day
2 day
3 day
0
20
40
60
80
100
120
140
160
Control FP 10-6M FP 10-7M FP 10-6M/day FP 10-7M/day
Treatments
#
Ce
lls
/F
ie
ld
1 day
2 day
3 day
77
Effect of TGF-methioninase on MCF-7 Cancer Cells
TGF-methioninase over concentration range of 10-8 M to 10-6 M in general did
not show any response in inhibition of cell migration and proliferation of MCF-7 breast
cancer cells over a period of 3 days (Figure 4.13). The exceptions where there was a
slight statistically significant (p<0.05) inhibition were at 10-6 M on days 2 and 3 for
proliferation and day 3 for migration [97]. One main reason for this non-inhibitory effect
is due to the internalization of ligand after binding to the TGF receptor. Upon binding of
TGF-methioninase, the TGF receptor at the cell surface gets phosphorylated and
propagates the signal to the cell nucleus for cell proliferation. After ligand binding, the
TGF receptor is internalized and partially degraded in lysosomes. The inhibition caused
by TGF-methioninase at concentration of 10 -6 M could be due to the excess exogeneous
present in the media. Based on these results, the approach of targeting L-methioninase to
overexpressed TGF receptors was not pursued further.
78
Figure 4.13. Effect of TGF-methioninase fusion protein on MCF-7 breast cancer cell
migration and proliferation. Each bar in the top panel represents the maximum distance
traveled by cells in the wounded area (mean ± SEM from 10 to 12 microscope fields).
Each bar in the bottom panel represents number of viable cells in the wounded area
(mean ± SEM from 10 to 12 microscope fields).
Treatments
1 day
#
Ce
lls
/F
ie
ld
0
20
40
60
80
100
120
140
160
180
Control TGF-meth 10-6M TGF-meth 10-7M TGF-meth 10-8M
2 day
3 day
0
0.05
0.1
0.15
0.2
0.25
0.3
Treatments
Fr
o
n
t
D
is
ta
n
c
e
(m
m
)
1
2
3
Control TGF-Meth10-6 M TGF-Meth 10-6 M TGF-Meth10-8 M
day
day
day
79
Specific Binding of ATF-methioninase to MCF-7 Cells
Previously, it was found that ATF-methioninase binds specifically to the
urokinase receptor on MCF-7 breast cancer cells, which was demonstrated by measuring
the displacement of ATF-methioninase with the increasing concentrations of urokinase
[93]. In this present study, the specific binding of ATF-methioninase fusion protein to
cancer cells was also measured by immunocytochemical localization [95]. The binding of
the fusion protein to MCF-7 cells was demonstrated using a specific L-methioninase
antibody for immunocytochemistry. As shown in Figure 4.14, the treatment of cells with
ATF-methioninase fusion protein (FP), or mutated FP resulted in a positive
immunolocalization at the cell membrane, indicated by the red brown staining of the
antibody specific to L-methioninase. Immunolocalization was not observed with cells
treated with ATF-methioninase fusion protein and urokinase, indicating a specific
displacement of fusion protein by urokinase. Further, immunolocalization was not
observed for cells treated with L-methioninase alone. ATF-methioninase fusion
protein did not get internalized because the ATF does not have a catalytic domain, which
is essential for the internalization [62]. This allows ATF-methioninase fusion protein to
remain bound on the cell surface.
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Figure 4.14. Photomicrographs (40X) of MCF-7 cells treated for 18 hours with either:
vehicle control (C); ATF-methioninase fusion protein (FP); mutated ATF-methioninase
(M-FP); L-methioninase (L-M); or fusion protein + urokinase (UK+FP). All treatments
were for 18 hours at a concentration of 10-6 M. The red/brown color represents positive
staining of the L-methioninase-specific primary antibody.
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Mouse Xenograft Assay
The influence of ATF-methioninase on the growth of MCF-7 breast cancer cells
in nude mouse xenografts was studied for a period of 20 days. The tumor volume and the
nude mouse weight were measured during the period of ATF-methioninase
administration. The top panel of Figure 4.15 indicates that there was no significant
change in the weight of the nude mice over the period of administration, indicating that
the mice were healthy over the period of administration and ATF-methioninase had no
adverse effects on the mice. The bottom panel of Figure 4.15 indicates that there was a
significant decrease in tumor volume for the mice treated with ATF-methioninase
compared to the mice treated with L-methioninase. This decrease in volume gives an
indication of the cancer cell growth inhibition by ATF-methioninase. After the mice were
euthanized, the cell number/mg of tissue was quantified by measuring -gal activity in
tissue homogenates. Figure 4.16 shows the results for the -gal activity in tumor tissue
after 20-day ATF-methioninase treatment. The ATF-methioninase produced more than a
four-fold reduction in cancer cell number/mg tumor tissue as compared to the vehicle-
treated control group, and more than a two-fold reduction in cell number/mg compared to
the group that received L-methioninase. This latter finding validates the hypothesis that
L-methioninase targeted to the cancer cell surface will be more effective in inhibiting cell
growth than free L-methioninase [95].
The effect of ATF-methioninase as shown in -gal activity measurement (Figure
4.16) was more when compared to the change in the tumor volumes (Figure 4.15). This
difference is due to the fact that the tumor contains a large fraction of connective tissue,
which occupies a significant volume even after the tumor cells die.
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Figure 4.16. Effect of a 20-day with ATF-methioninase or L-methioninase
treatment on the growth of MCF-7 tumors and in nude mouse xenografts. The
cell number/mg of tissue was quantified by measuring the -gal activity in
tissue homogenates (mean ± SEM). Ten animals were included in each group.
The treatment was administered by intra-tumoral injection.
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The main reason to deliver the ATF-methioninase to mouse xenografts intratumorally
was to reduce the loss of the fusion protein. Although this approach of delivering drugs is
rarely used in a clinical setting, it has many advantages over systemic delivery in
experimental studies like this one. This method makes it possible to deliver the exact and
known concentrations of the drug to the primary sites of the tumor. Due to this, the
amount of drug used will be minimum and much more effective. In a recent study,
intratumoral infusion placed stereotactically in a malignant glioma was used to deliver a
fusion protein consisting of IL-4 linked to Pseudomonas aeruginosa exotoxin A [109].
This resulted in a long term survival of a patient for three years after fusion protein
infusion with a durable tumor response. In another clinical application, eleven patients
suffering from metastastic breast and colorectal cancers and from malignant melanomas
were treated by intratumoral injection of a single chain antibody toxin fusion protein,
with complete regression of tumor nodules in 40 % of the patients and partial reduction in
tumor size in 20 % of the patients [110].
One drawback to the use of L-methioninase for more than few weeks in human
cancer therapy is the immunogenecity of bacterially derived L-methioninase. One way to
reduce the immunogenicity is to conjugate it to polyethylene glycol (PEG). L–
methioninase has been conjugated to PEG, resulting in a significant increase in serum
half life in rats and 36 fold increase in serum half life in primates and elimination of
anaphylactic reactions. [37, 38].
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Binding of Methioninase-Annexin V to Plastic-immobilized Phosphatidylserine
Methioninase-annexin specifically recognizes PS and binds strongly to plates
coated with PS in the presence of 10% bovine serum albumin. The results in Figure 4.17
show that the binding of methioninase-annexin V to PS immobilized on plastic plates
increased as its concentration increased. The control result for L-methioninase was very
low (A450 less than 10 % of that for methioninase-annexin V). One further control that
should be performed in the future is in which all the conditions are the same except no PS
is added. It is expected that neither methioninase-annexin V nor L-methioninase will
show any appreciable binding with no PS present.
Binding of Methioninase-Annexin V on Externally Positioned PS on the Surface of
MCF-7 Breast Cancer Cells
The binding of methioninase-annexin V to cell surfaces was examined using
MCF-7 breast cancer cells with hydrogen peroxide added in the medium to induce
exposure of PS on the cell surface. The results in Figure 4.18 indicate that the binding of
methioninase-annexin V to PS on the surface of MCF-7 breast cancer cells increased as
its concentration is increased, especially at concentrations above 0.3 nM. The binding of
the L-methioninase control was negligible. These results indicate specific binding of
methioninase-annexin V to PS on the surface of MCF-7 breast cancer cells.
All the experiments were done in the presence in the presence of Ca2+ because it
has been shown previously that binding of annexin V to PS is Ca2+ dependent and
binding of annexin V in its absence was found to bind most avidly to
phosphatidylcholine. Annexin V binds to other anionic phospholipids in the order of
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Figure 4.17. Binding of methioninase-annexin V to phosphatidylserine adsorbed to
plastic. Blank for assay: +1o Ab, +2o Ab. Control for assay (): L-methioninase, +1o Ab,
+2o Ab. (each A450 measured in triplicate).
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Figure 4.18. Binding of methioninase-annexin V to phosphatidylserine exposed on MCF-
7 breast cancer cells. Blank for assay: +1o Ab, +2o Ab. Control for assay (): L-
methioninase, +1o Ab, +2o Ab. (each A450 measured in triplicate).
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phosphatidylethanolamine, PS, cardiolipin, phosphatic acid, phosphatidylinositol, and
phosphatidylglycerol. It is known PS is exposed on apoptotic cells, aging cells and
activated platelets, and methioninase-annexin V is expected to bind to these cells.
However, methioninase is not toxic to these cells, so binding to these cells is of less
concern. Another advantage using annexin V as targeting molecule other than its
abundant exposure on tumor vessel endothelial cells (> 106 molecules per cell) is that
ease of application of methioninase-annexin V intraperitoneally in the mouse xenograft
models. Diffusional limitations of the drugs to core of tumor sites is eliminated by using
methioninase-annexin V because binding of methioninase-annexin at tumor vasculature
may be effective as complete diffused drug in the tumor site.
5. CONCLUSIONS
The major objective of this work was to examine three fusion proteins (ATF-
methioninase, TGF-methioninase, and methioninase-annexin V) for targeting the human
cancer cells selectively and inhibiting the migration and proliferation of the cells. A
secondary objective was to evaluate the ability of the methioninase-annexin fusion
protein to bind selectively to plastic-immobilized PS and to PS exposed on the surface of
cancer cells.
The three fusion proteins were expressed as soluble proteins and purified to
homogeneity from the pET-30 Ek/LIC and pET-44 Ek/LIC vector expression systems.
Use of the pET-44 Ek/LIC vector introduced a NusA protein tag to TGF-methioninase.
All of the fusion proteins expressed had an N-terminal His6 tag to facilitate purification
by immobilized metal affinity chromatography. An HRV 3C protease site was
incorporated after the enterokinase site, and HRV 3C protease was found effective in
cleavage of the His6 tag. Flash freezing in liquid nitrogen in buffer with 100 mM NaCl
followed by lyophilization was found to the most effective way to store the samples for
longer period of times. This process resulted in proteins with purities above 90%
consistently.
Based on the results of the culture wounding assays using MCF-7 breast cancer
cells, SK-LU-1 lung cancer cells, and PC-3 prostate cancer cells, ATF-methioninase was
significantly more effective than free L-methioninase in vitro in inhibiting cell
proliferation and migration. In the culture wounding tests, it was found that cytotoxicity
to cancer cells was caused by methioninase activity alone. Treatment with TGF-
methioninase in general did not show any inhibition of the proliferation and migration of
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MCF-7 cells. ATF-methioninase with the L-methioninase mutated to give no activity
gave negligible inhibition of cancer cell proliferation and migration. ATF-methioninase
bound specifically to MCF-7 breast cancer cells and did not internalize upon binding to
the uPAR. Treatment of s.c. implanted MCF-7 breast cancer cells mouse xenografts with
ATF-methioninase gave significantly more tumor regression when compared to mouse
xenografts treated with L-methioninase alone.
The methioninase-annexin V fusion protein bound specifically to PS immobilized
on plastic plates as well as on the surface of MCF-7 cancer cells in which PS was induced
to be on the surface by the addition of hydrogen peroxide.
Based on the results obtained in this research, future research methods should
include full length ATF (135 amino acids) in fusion with L-methioninase, 2) pegylation
of ATF-methioninase to reduce the immunogenicity, 3) testing the ATF-methioninase
with other cancer cell types like colon, melanoma, and ovarian, 4) testing the binding of
methioninase-annexin V fusion protein to human endothelial cells grown in vitro on
which PS has been induced to be exposed on the surface, 5) finally, testing the effect of
methioninase-annexin V fusion protein injected i.p. in mice on the growth of tumor
xenografts.
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APPENDIX A
Primers for PCR of Carrier and Target Genes
The general design and use of these primers is described in the Methods section.
The particular enzyme sequence (or other relevant sequence) within each primer is also
indicated.
1) Primers for L-methioninase with BamHI site at 5’ end
Meth 5’ Primer
5’ – CgC / ggA / TCC / CgC / gAC / TCC / CAT / AAC / AAC / ACC – 3’
Meth 3’ Primer
5’ – gAg / gAg / AAg / CCC / ggT / TAT / CAT / gCA / CAC / gCC / TCC / AAT / gCC
/ AAC / TCg – 3’
2) Primers for TGF with 5’ LIC end
TGF 5’ Primer
5’ – gAC / gAC / gAC / AAg / ATg / ggA / gTg / gTg / TCC / CAT / TTT / AAT / gAC /
TgC / CC – 3’
TGF 3’ Primer
5’ – gC / ggA / TCC / AgA / ACC / gCT / gCC / AgC / CAg / gAg gTC / CgC / ATg /
CTC / ACA / gCg – 3’
TGF 3C 5’ Primer
5’ – gAC / gAC / gAC / AAg / ATg / CTT / gAA / gTC / CTC / TTT / CAg / ggA / gTg /
gTg / TCC / CAT / TTT / AAT / gAC / TgC / CC – 3’
3) Primers to mutate ATF-methioninase
mutMeth 5’ Primer
5’ – gCg / CAC / CTT / gTT / Tgg / CTg / CAC / CTT / Tg – 3’
mutMeth 3’ Primer
5’ – CAA / Agg / TgC / AgC / CAA / ACA / Agg / TgC / gC – 3’
4) 5’ Primer for urokinase
Uro 5’ Primer
5’ – gAC / gAC / gAC / AAg / ATg / AgC / AAT / gAA / CTT / CAT / CAA / gTT / CC
– 3’
5) 5’ Primer for urokinase with 3C site
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Uro 3C 5’ Primer
5’ - gAC / gAC / gAC / AAg / ATg / CTT / gAA / gTC / CTC / TTT / CAg / ggA / CCC
/ AgC / AAT / gAA / CTT / CAT / CAA / gTT / CC – 3’
Meth 3C 5’ Primer
5’ – gAC / gAC / gAC / AAg / ATg / CTT / gAA / gTC / CTC / TTT / CAg / ggA / CCC
/ CgC / gAC / TCC / CAT / AAC / AAC / ACC – 3’
Methhexalysine 3’ Primer
5’ – gAg / gAg / AAg / CCC / ggT / TAT / TTC / TTT / TTC / TTC / TTT / TTT / CCA /
gAA / CCg / CTg / CCT / gCA / CAC / gCC / TCC / AAT / gCC / AAC / TCg – 3’
AnnexinMeth 5’ Primer
5’- Cg / ATT / CgC / ggA / TCC / gCA / CAg / gTT / CTC / AgA / ggC – 3’
Annexin 3’ Primer
5’ – gAg / gAg / AAg / CCC / ggT / TAg / TCA / TCT / TCT / CCA / CAg / AgC – 3’
Methxin 3’ Primer
5’ - gC / CgC / ATT / ggA / TCC / AgA / ACC / gCT / gCC / TgC / ACA / CgC / CTC /
CAA / TgC / CAA / CTC / g – 3’
Annexin 5’ Primer
5’ – gAC / gAC / gAC / AAg / ATg / CTT / gAA / gTC / CTC / TTT / CAg / gCA / CAg
/ gTT / CTC / AgA / ggC – 3’
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Sequencing Results for the ATF/Methioninase Fusion Gene.
ATF ->  
agcaatgaacttcatcaagttccatcgaactgtgactgtctaaatggaggaacatgtgtg
S N E L H Q V P S N C D C L N G G T C V
tccaacaagtacttctccaacattcactggtgcaactgcccaaagaaattcggagggcag
S N K Y F S N I H W C N C P K K F G G Q
BamHI Methioninase -> 
cactgtgaaatagataagtcaaaaaccggcagcggttctggatcccgcgactcccataac
H C E I D K S K T G S G S G S R D S H N
aacaccggtttttccacacgggccattcaccacggctacgacccgctttcccacggtggt
N T G F S T R A I H H G Y D P L S H G G
gccttggtgccaccggtgtaccagaccgcgacctatgccttcccgactgtcgaatacggc
A L V P P V Y Q T A T Y A F P T V E Y G
gctgcgtgcttcgccggggaggaggcggggcacttctacagccgcatctccaaccccacc
A A C F A G E E A G H F Y S R I S N P T
ctggccttgctcgagcaacgcatggcctcgttggagggtggtgaggcgggattggcgctg
L A L L E Q R M A S L E G G E A G L A L
gcgtcggggatgggagccattacttcgaccctctggaccctgctgcggcctggtgatgag
A S G M G A I T S T L W T L L R P G D E
ctgatcgtggggcgcaccttgtatggctgcacctttgcgttcctgcaccatggcattggc
L I V G R T L Y G C T F A F L H H G I G
gagttcggggtcaagatccaccatgtcgaccttaacgatgccaaggccctgaaagcggcg
E F G V K I H H V D L N D A K A L K A A
atcaacagcaaaacgcggatgatctacttcgaaacaccggccaaccccaacatgcaactg
I N S K T R M I Y F E T P A N P N M Q L
gtggatatagcggcggtcgtcgaggcagtgcgggggagtgatgtgcttgtggtggtcgac
V D I A A V V E A V R G S D V L V V V D
aacacctactgcacgccctacctgcagcggccactggaactgggggcagacctggtggtg
N T Y C T P Y L Q R P L E L G A D L V V
cattcggcaaccaagtacctcagtggccatggcgacatcactgcgggcctggtggtgggg
H S A T K Y L S G H G D I T A G L V V G
cgcaaggctttggtcgaccgcattcggctggaagggctgaaagacatgaccggggcagcc
R K A L V D R I R L E G L K D M T G A A
ttgtcaccgcatgacgctgcgttgttgatgcgcggcatcaagaccctggcgctgcgcatg
L S P H D A A L L M R G I K T L A L R M
gaccggcattgcgccaacgccctggaggtcgcgcagttcctggccgggcagccccaggtg
D R H C A N A L E V A Q F L A G Q P Q V
gagctgatccactacccgggcttgccgtcgtttgcccagtacgaactggcacagcggcag
E L I H Y P G L P S F A Q Y E L A Q R Q
atgcgtttgccgggcgggatgattgcctttgagctcaagggcggtatcgaggccgggcgc
M R L P G G M I A F E L K G G I E A G R
ggcttcatgaatgccctgcagctttttgcccgtgcggtgagcctgggggatgccgagtcg
G F M N A L Q L F A R A V S L G D A E S
ctggcacagcacccggcgagcatgacgcactccagttacacgccacaagagcgggcgcat
L A Q H P A S M T H S S Y T P Q E R A H
cacgggatatcagaggggctggtgaggttgtcagtggggctggaggatgtggaggacctg
H G I S E G L V R L S V G L E D V E D L
ctggcagatatcgagttggcgttggaggcgtgtgcatga
L A D I E L A L E A C A -
GenBank sequences used for comparison
ATF: NM_002658
Methioninase: PSEMEGL
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Sequencing Results for the TGF/Methioninase Fusion Gene.
TGF
ggagtggtgtcccattttaatgactgcccagattcccacactcagttctgcttccatgga
G V V S H F N D C P D S H T Q F C F H G
acatgcaggtttttggtgcaggaggacaagccggcatgtgtctgccattctgggtacgtt
T C R F L V Q E D K P A C V C H S G Y V
Methioninase 
ggtgcgcgctgtgagcatgcggacctcctggctggcagcggttctggatcccgcgactcc
G A R C E H A D L L A G S G S G S R D S
cataacaacaccggtttttccacacgggccattcaccacggctacgacccgctttcccac
H N N T G F S T R A I H H G Y D P L S H
ggtggtgccttggtgccaccggtgtaccagaccgcgacctatgccttcccgactgtcgaa
G G A L V P P V Y Q T A T Y A F P T V E
tacggcgctgcgtgcttcgccggggaggaggcggggcacttctacagccgcatctccaac
Y G A A C F A G E E A G H F Y S R I S N
cccaccctggccttgctcgagcaacgcatggcctcgttggagggtggtgaggcgggattg
P T L A L L E Q R M A S L E G G E A G L
gcgctggcgtcggggatgggagccattacttcgaccctctggaccctgctgcggcctggt
A L A S G M G A I T S T L W T L L R P G
gatgagctgatcgtggggcgcaccttgtatggctgcacctttgcgttcctgcaccatggc
D E L I V G R T L Y G C T F A F L H H G
attggcgagttcggggtcaagatccaccatgtcgaccttaacgatgccaaggccctgaaa
I G E F G V K I H H V D L N D A K A L K
gcggcgatcaacagcaaaacgcggatgatctacttcgaaacaccggccaaccccaacatg
A A I N S K T R M I Y F E T P A N P N M
caactggtggatatagcggcggtcgtcgaggcagtgcgggggagtgatgtgcttgtggtg
Q L V D I A A V V E A V R G S D V L V V
gtcgacaacacctactgcacgccctacctgcagcggccactggaactgggggcagacctg
V D N T Y C T P Y L Q R P L E L G A D L
gtggtgcattcggcaaccaagtacctcagtggccatggcgacatcactgcgggcctggtg
V V H S A T K Y L S G H G D I T A G L V
gtggggcgcaaggctttggtcgaccgcattcggctggaagggctgaaagacatgaccggg
V G R K A L V D R I R L E G L K D M T G
gcagccttgtcaccgcatgacgctgcgttgttgatgcgcggcatcaagaccctggcgctg
A A L S P H D A A L L M R G I K T L A L
cgcatggaccggcattgcgccaacgccctggaggtcgcgcagttcctggccgggcagccc
R M D R H C A N A L E V A Q F L A G Q P
caggtggagctgatccactacccgggcttgccgtcgtttgcccagtacgaactggcacag
Q V E L I H Y P G L P S F A Q Y E L A Q
cggcagatgcgtttgccgggcgggatgattgcctttgagctcaagggcggtatcgaggcc
R Q M R L P G G M I A F E L K G G I E A
gggcgcggcttcatgaatgccctgcagctttttgcccgtgcggtgagcctgggggatgcc
G R G F M N A L Q L F A R A V S L G D A
gagtcgctggcacagcacccggcgagcatgacgcactccagttacacgccacaagagcgg
E S L A Q H P A S M T H S S Y T P Q E R
gcgcatcacgggatatcagaggggctggtgaggttgtcagtggggctggaggatgtggag
A H H G I S E G L V R L S V G L E D V E
gacctgctggcagatatcgagttggcgttggaggcgtgtgca
D L L A D I E L A L E A C A
GenBank sequences used for comparison
Methioninase: PSEMEGL
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Sequencing Results for the Methioninase Gene.
Methioninase -> 
cgcgactcccataacaacaccggtttttccacacgggccattcaccacggctacgacccg
R D S H N N T G F S T R A I H H G Y D P
ctttcccacggtggtgccttggtgccaccggtgtaccagaccgcgacctatgccttcccg
L S H G G A L V P P V Y Q T A T Y A F P
actgtcgaatacggcgctgcgtgcttcgccggggaggaggcggggcacttctacagccgc
T V E Y G A A C F A G E E A G H F Y S R
atctccaaccccaccctggccttgctcgagcaacgcatggcctcgttggagggtggtgag
I S N P T L A L L E Q R M A S L E G G E
gcgggattggcgctggcgtcggggatgggagccattacttcgaccctctggaccctgctg
A G L A L A S G M G A I T S T L W T L L
cggcctggtgatgagctgatcgtggggcgcaccttgtatggctgcacctttgcgttcctg
R P G D E L I V G R T L Y G C T F A F L
caccatggcattggcgagttcggggtcaagatccaccatgtcgaccttaacgatgccaag
H H G I G E F G V K I H H V D L N D A K
gccctgaaagcggcgatcaacagcaaaacgcggatgatctacttcgaaacaccggccaac
A L K A A I N S K T R M I Y F E T P A N
cccaacatgcaactggtggatatagcggcggtcgtcgaggcagtgcgggggagtgatgtg
P N M Q L V D I A A V V E A V R G S D V
cttgtggtggtcgacaacacctactgcacgccctacctgcagcggccactggaactgggg
L V V V D N T Y C T P Y L Q R P L E L G
gcagacctggtggtgcattcggcaaccaagtacctcagtggccatggcgacatcactgcg
A D L V V H S A T K Y L S G H G D I T A
ggcctggtggtggggcgcaaggctttggtcgaccgcattcggctggaagggctgaaagac
G L V V G R K A L V D R I R L E G L K D
atgaccggggcagccttgtcaccgcatgacgctgcgttgttgatgcgcggcatcaagacc
M T G A A L S P H D A A L L M R G I K T
ctggcgctgcgcatggaccggcattgcgccaacgccctggaggtcgcgcagttcctggcc
L A L R M D R H C A N A L E V A Q F L A
gggcagccccaggtggagctgatccactacccgggcttgccgtcgtttgcccagtacgaa
G Q P Q V E L I H Y P G L P S F A Q Y E
ctggcacagcggcagatgcgtttgccgggcgggatgattgcctttgagctcaagggcggt
L A Q R Q M R L P G G M I A F E L K G G
atcgaggccgggcgcggcttcatgaatgccctgcagctttttgcccgtgcggtgagcctg
I E A G R G F M N A L Q L F A R A V S L
ggggatgccgagtcgctggcacagcacccggcgagcatgacgcactccagttacacgcca
G D A E S L A Q H P A S M T H S S Y T P
caagagcgggcgcatcacgggatatcagaggggctggtgaggttgtcagtggggctggag
Q E R A H H G I S E G L V R L S V G L E
gatgtggaggacctgctggcagatatcgagttggcgttggaggcgtgtgcatga
D V E D L L A D I E L A L E A C A -
GenBank sequences used for comparison
Methioninase: PSEMEGL
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Sequencing Results for the Methioninase-annexin V Fusion Gene.
Methioninase -> 
cgcgactcccataacaacaccggtttttccacacgggccattcaccacggctacgacccg
R D S H N N T G F S T R A I H H G Y D P
ctttcccacggtggtgccttggtgccaccggtgtaccagaccgcgacctatgccttcccg
L S H G G A L V P P V Y Q T A T Y A F P
actgtcgaatacggcgctgcgtgcttcgccggggaggaggcggggcacttctacagccgc
T V E Y G A A C F A G E E A G H F Y S R
atctccaaccccaccctggccttgctcgagcaacgcatggcctcgttggagggtggtgag
I S N P T L A L L E Q R M A S L E G G E
gcgggattggcgctggcgtcggggatgggagccattacttcgaccctctggaccctgctg
A G L A L A S G M G A I T S T L W T L L
cggcctggtgatgagctgatcgtggggcgcaccttgtatggctgcacctttgcgttcctg
R P G D E L I V G R T L Y G C T F A F L
caccatggcattggcgagttcggggtcaagatccaccatgtcgaccttaacgatgccaag
H H G I G E F G V K I H H V D L N D A K
gccctgaaagcggcgatcaacagcaaaacgcggatgatctacttcgaaacaccggccaac
A L K A A I N S K T R M I Y F E T P A N
cccaacatgcaactggtggatatagcggcggtcgtcgaggcagtgcgggggagtgatgtg
P N M Q L V D I A A V V E A V R G S D V
cttgtggtggtcgacaacacctactgcacgccctacctgcagcggccactggaactgggg
L V V V D N T Y C T P Y L Q R P L E L G
gcagacctggtggtgcattcggcaaccaagtacctcagtggccatggcgacatcactgcg
A D L V V H S A T K Y L S G H G D I T A
ggcctggtggtggggcgcaaggctttggtcgaccgcattcggctggaagggctgaaagac
G L V V G R K A L V D R I R L E G L K D
atgaccggggcagccttgtcaccgcatgacgctgcgttgttgatgcgcggcatcaagacc
M T G A A L S P H D A A L L M R G I K T
ctggcgctgcgcatggaccggcattgcgccaacgccctggaggtcgcgcagttcctggcc
L A L R M D R H C A N A L E V A Q F L A
gggcagccccaggtggagctgatccactacccgggcttgccgtcgtttgcccagtacgaa
G Q P Q V E L I H Y P G L P S F A Q Y E
ctggcacagcggcagatgcgtttgccgggcgggatgattgcctttgagctcaagggcggt
L A Q R Q M R L P G G M I A F E L K G G
atcgaggccgggcgcggcttcatgaatgccctgcagctttttgcccgtgcggtgagcctg
I E A G R G F M N A L Q L F A R A V S L
ggggatgccgagtcgctggcacagcacccggcgagcatgacgcactccagttacacgcca
G D A E S L A Q H P A S M T H S S Y T P
caagagcgggcgcatcacgggatatcagaggggctggtgaggttgtcagtggggctggag
Q E R A H H G I S E G L V R L S V G L E
gatgtggaggacctgctggcagatatcgagttggcgttggaggcgtgtgcaggcagcggt
D V E D L L A D I E L A L E A C A G S G
Annexin-> 
tctggatccgcacaggttctcagaggcactgtgactgactgccctggatttgatgagcgg
S G S A Q V L R G T V T D C P G F D E R
gctgatgcagaaactcttcggaaggctatgaaaggcttgggcacagatgaggagagcatc
A D A E T L R K A M K G L G T D E E S I
ctgactctgttgacatcccgaagtaatgctcagcgccaggaaatctctgcagcttttaag
L T L L T S R S N A Q R Q E I S A A F K
actctgtttggcagggatcttctggatgacctgaaatcagaactaactggaaaatttgaa
T L F G R D L L D D L K S E L T G K F E
…CONTD
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aaattaattgtggctctgatgaaaccctctcggctttatgatgcttatgaactgaaacat
K L I V A L M K P S R L Y D A Y E L K H
gccttgaagggagctggaacaaatgaaaaagtactgacagaaattattgcttcaaggaca
A L K G A G T N E K V L T E I I A S R T
cctgaagaactgagagccatcaaacaagtttatgaagaagaatatggctcaagcctggaa
P E E L R A I K Q V Y E E E Y G S S L E
gatgacgtggtgggggacacttcagggtactaccagcggatgttggtggttctccttcan
D D V V G D T S G Y Y Q R M L V V L L X
gctaacagagaccctgatgctggaatcgatgaagctcnagttgaacaagatgctcangct
A N R D P D A G I D E A X V E Q D A X A
ttatttcaggctggagaacttaaatgggggacagatgaagaaaagtttatcaccatcttt
L F Q A G E L K W G T D E E K F I T I F
ggaacacgaagtgtgtctcatttgagaaaggtgtttgacaagtacatgactatatcagga
G T R S V S H L R K V F D K Y M T I S G
tttcaaattgaggaaaccattgaccgcgagacttctggcaatttagagcaaatatcagga
F Q I E E T I D R E T S G N L E Q I S G
tttcaaattgaggaaaccattgaccgcgagacttctggcaatttagagcaatattatgct
F Q I E E T I D R E T S G N L E Q Y Y A
atgaagggagctgggacagatgatcataccctcatcagagtcatggtttccaggagtgag
M K G A G T D D H T L I R V M V S R S E
attgatctgtttaacatcaggaaggagtttaggaagaattttgccacctctctttattcc
I D L F N I R K E F R K N F A T S L Y S
atgattaagggagatacatctggggactataagaaagctcttctgctgctctgtggagaa
M I K G D T S G D Y K K A L L L L C G E
gatgac
D D
GenBank sequences used for comparison
Methioninase: PSEMEGL
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APPENDIX B
QIAquick PCR Purification Kit Protocol
Fragments ranging from 100 bp to 10 kb are purified from primers,
nucleotides, polymerases, and salts using QIAquick spin columns in a microcentrifuge.
Notes:
• Add ethanol (96–100%) to Buffer PE before use (see bottle label for volume).
• All centrifuge steps are at 13,000 rpm (~17,900 x g) in a conventional tabletop
microcentrifuge.
1. Add 5 volumes of Buffer PB to 1 volume of the PCR sample and mix. It is not
necessary to remove mineral oil or kerosene. For example, add 500 µl of Buffer
PB to 100 µl PCR sample (not including oil).
2. Place a QIAquick spin column in a provided 2 ml collection tube.
3. To bind DNA, apply the sample to the QIAquick column and centrifuge for 30–60
s.
4. Discard flow-through. Place the QIAquick column back into the same tube.
Collection tubes are re-used to reduce plastic waste.
5. To wash, add 0.75 ml Buffer PE to the QIAquick column and centrifuge for 30–
60 s.
6. Discard flow-through and place the QIAquick column back in the same tube.
Centrifuge the column for an additional 1 min.
IMPORTANT: Residual ethanol from Buffer PE will not be completely removed
unless the flow-through is discarded before this additional centrifugation.
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7. Place QIAquick column in a clean 1.5 ml microcentrifuge tube.
8. To elute DNA, add 50 µl Buffer EB (10 mM Tris·Cl, pH 8.5) or H2O to the center
of the QIAquick membrane and centrifuge the column for 1 min.
QIAquick Gel Extraction Kit Protocol
This protocol is designed to extract and purify DNA of 70 bp to 10 kb from standard or
low-melt agarose gels in TAE or TBE buffer. Up to 400 mg agarose can be processed per
spin column. For DNA cleanup from enzymatic reactions using this protocol, add 3
volumes of BufferQG and 1 volume of isopropanol to the reaction, mix, and proceed with
step 6 of the protocol.
• The yellow color of Buffer QG indicates a pH 7.5.
• Add ethanol (96–100%) to Buffer PE before use (see bottle label for volume).
• Isopropanol (100%) and a heating block or water bath at 50°C are required.
• All centrifugation steps are carried out at 13,000 rpm (~17,900 x g) in a
conventional table-top microcentrifuge.
• 3 M sodium acetate, pH 5.0, may be necessary.
1. Excise the DNA fragment from the agarose gel with a clean, sharp scalpel.
Minimize the size of the gel slice by removing extra agarose.
2. Weigh the gel slice in a colorless tube. Add 3 volumes of Buffer QG to 1 volume
of gel (100 mg ~ 100 µl). For example, add 300 µl of Buffer QG to each 100 mg
of gel. For >2% agarose gels, add 6 volumes of Buffer QG. The maximum
amount of gel slice per QIAquick column is 400 mg; for gel slices >400 mg use
more than one QIAquick column.
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3. Incubate at 50°C for 10 min (or until the gel slice has completely dissolved). To
help dissolve gel, mix by vortexing the tube every 2–3 min during the incubation.
IMPORTANT: Solubilize agarose completely. For >2% gels, increase incubation
time.
4. After the gel slice has dissolved completely, check that the color of the mixture is
yellow (similar to Buffer QG without dissolved agarose). If the color of the
mixture is orange or violet, add 10 µl of 3 M sodium acetate, pH 5.0, and mix.
The color of the mixture will turn to yellow. The adsorption of DNA to the
QIAquick membrane is efficient only at pH 7.5. Buffer QG contains a pH
indicator which is yellow at pH 7.5 and orange or violet at higher pH, allowing
easy determination of the optimal pH for DNA binding. 5. Add 1 gel volume of
isopropanol to the sample and mix. For example, if the agarose gel slice is 100 mg,
add 100 µl isopropanol. This step increases the yield of DNA fragments <500 bp
and >4 kb. For DNA fragments between 500 bp and 4 kb, addition of isopropanol
has no effect on yield. Do not centrifuge the sample at this stage.
5. Place a QIAquick spin column in a provided 2 ml collection tube.
To bind DNA, apply the sample to the QIAquick column, and centrifuge for 1
min. The maximum volume of the column reservoir is 800 µl. For sample
volumes of more than 800 µl, simply load and spin again.
6. Discard flow-through and place QIAquick column back in the same collection
tube. Collection tubes are re-used to reduce plastic waste.
7. (Optional): Add 0.5 ml of Buffer QG to QIAquick column and centrifuge for 1
min. This step will remove all traces of agarose. It is only required when the DNA
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will subsequently be used for direct sequencing, in vitro transcription or
microinjection.
8. To wash, add 0.75 ml of Buffer PE to QIAquick column and centrifuge for 1 min.
Note: If the DNA will be used for salt sensitive applications, such as blunt-end
ligation and direct sequencing, let the column stand 2–5 min after addition of
Buffer PE, before centrifuging.
9. Discard the flow-through and centrifuge the QIAquick column for an additional 1
min at 13,000 rpm (~17,900 x g).
IMPORTANT: Residual ethanol from Buffer PE will not be completely removed
unless the flow-through is discarded before this additional centrifugation.
10. Place QIAquick column into a clean 1.5 ml microcentrifuge tube.
11. To elute DNA, add 50 µl of Buffer EB (10 mM Tris·Cl, pH 8.5) or H2O to the
center of the QIAquick membrane and centrifuge the column for 1 min.
Agarose Gel Elecrophoresis
The following protocol is for making a 1% (w/v) agarose gel using SeaKem® LE agarose
(Cambrex) using a BRL Life Technologies Horizon 58 electrophoretic cell with a total
gel volume of 35 ml.
1. Assemble the electrophoretic cell.
2. Weigh out 0.35 g of agarose in a beaker. Add 35 ml of 1X TAE buffer (40 mM
Tris-acetate, 1 mM EDTA). Microwave on high for 90 sec. Let the solution cool
to 55oC and add 35 µl of 0.5 mg/ml ethidium bromide stock (mix the solution
112
well to evenly distribute the ethidium bromide). Pour the gel into the cell and wait
20-30 min for solidification.
3. Add 5 ml of 50X TAE buffer and 250 µl of 0.5 mg/ml ethidium bromide to 245
ml of dH2O. Once the gel has solidified pour the TAE/EtBr solution over the gel
until it covers the gel by about 1mm. The gel is now ready to be loaded.
4. To each DNA sample to be loaded, add 5 µl of gel loading buffer (GLB). The
composition of GLB is 0.25% (w/v) bromophenol blue and 30% (v/v) glycerol in
water. The maximum volume of DNA sample is 20 µl for each well of the 8 comb
gel which has a total volume of 25 µl.
5. For the marker lane add 2 µl of 1 kB ladder to 3 µl water and 1 µl GLB mixture.
Site Directed Mutagenesis by Stratagene
This is the protocol followed to create the mutation on ATF-methioninase gene.
1. Mutant Strand Synthesis Reaction (Thermal Cycling)
Prepare the control reaction as indicated below:
Volume Component
5 µl 10× reaction buffer
2 µl (10 ng) pWhitescript 4.5-kb control plasmid (5 ng/µl)
1.25 µl (125 ng) Oligonucleotide control primer #1
1.25 µl (125 ng) Oligonucleotide control primer #2
1 µl dNTP mix
39.5 µl Double-distilled water (ddH2O)
1 µl PfuTurbo DNA polymerase (2.5 U/µl)
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Prepare the sample reaction(s) as indicated below:
Volume Component
5 µl 10× reaction buffer
X µl (5–50 ng) dsDNA template
X µl (125 ng) Oligonucleotide control primer #1
X µl (125 ng) Oligonucleotide control primer #2
1 µl dNTP mix
Y µl Double-distilled water (ddH2O)
1 µl PfuTurbo DNA polymerase (2.5 U/µl)
Cycling Parameters
2. Dpn I enzyme digestion
o Add 1 µl of the Dpn I restriction enzyme (10 U/µl) directly to each
amplification reaction below the mineral oil overlay using a small, pointed
pipet tip.
o Gently and thoroughly mix each reaction mixture by pipetting the solution up
and down several times. Spin down the reaction mixtures in a microcentrifuge
for 1 min and immediately incubate each reaction at 37°C for 1 h to digest the
parental (i.e., the nonmutated) supercoiled dsDNA.
Segment Cycles Temperature Time
1 1 95 oC 30 s
95 oC 30 s
55 oC 1 min
2 12
68 oC 7 min
3  4 oC  min
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Transformation of XL1-Blue Supercompetent Cells
o Gently thaw the XL1-Blue supercompetent cells on ice. For each control and
sample reaction to be transformed, aliquot 50 µl of the supercompetent cells to
a prechilled 14-ml BD Falcon polypropylene round-bottom tube.
o Transfer 1 µl of the Dpn I-treated DNA from each control and sample reaction
to separate aliquots of the supercompetent cells.
o Heat pulse the transformation reactions for 45 seconds at 42°C and then place
the reactions on ice for 2 min.
o Add 0.5 ml of NZY+ brothpreheated to 42°C and incubate the transformation
reactions at 37°C for 1 h with shaking at 225–250 rpm.
o Plate the appropriate volume of each transformation reaction, on agar plates
containing the appropriate antibiotic for the plasmid vector.
o Incubate the transformation plates at 37°C for >16 h.
Transformation protocol (For NovaBlue and BL21 (DE3) cells)
1. Thaw the required number of tubes of cells on ice and mix gently to ensure that
the cells are evenly suspended.
2. Place the required number of 1.5-ml polypropylene microcentrifuge tubes on ice
to pre-chill. Pipet 20 µl aliquots of cells into the pre-chilled tubes.
3. Add 1 µl of the DNA solution directly to the cells. Stir gently to mix.
4. Place the tubes on ice for 5 min.
5. Heat the tubes for exactly 30 s in a 42°C water bath; do not shake.
6. Place on ice for 2 min.
7. Add 80 µl of room temperature SOC Medium to each tube.
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8. Incubate at 37°C while shaking at 250 rpm for 60 min prior to plating on selective
medium.
Ligation Independent Cloning (LIC) Protocol
PCR of gene
1. Amplify the desired insert sequence using appropriately designed PCR primers.
2. The PCR product must be purified to completely remove the dNTPs, to inactivate
the enzyme used for PCR, and to remove interfering DNA. This is done by using
the Qiagen PCR purification protocol.
T4 DNA Polymerase treatment of target insert
1. Assemble the following components in a sterile 1.5-ml microcentrifuge tube kept on
ice:
• x µl 0.2 pmol purified PCR product.
• 2 µl 10X T4 DNA polymerase buffer
• 2 µl 25 mM dATP
• 1 µl 100 mM DTT
• y µl nuclease-free water (add to make 20 µl total volume)
• 0.4 µl 2.5 U/µl T4 DNA Polymerase (LIC-qualified; 0.5 unit per 0.1
pmol PCR product)
• 20 µl total volume (Final concentration of insert is 0.01 pmol/µl.) 
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2. Start reaction by adding enzyme; stir with pipet tip to mix and incubate at 22°C for 30
min.
3. Inactivate enzyme by incubating at 75°C for 20 min.
4. This prepared insert can be annealed to any of the Ek/LIC vectors. Store prepared
Ek/LIC insert.
Annealing the Vector and Ek/LIC Insert
1. For each insert, assemble the following components in a sterile 1.5-ml microcentrifuge
tube:
• 1 µl Ek/LIC vector
• 2 µl T4 DNA polymerase treated Ek/LIC insert (0.02 pmol)
Incubate at 22°C for 5 min, then add:
• 1 µl 25 mM EDTA
2. Mix by stirring with the pipet tip and incubate at 22°C for 5 min.
3.Transform the annealed product into NovaBlue Cells using the protocol described in
Appendix B.
Bio-Rad’s Protein Assay
1. Mix
a. 5 to 200 µl of enzyme sample
b. 200 µl of concentrated Biorad reagent
c. x µl of water to make a volume to 1 ml
2. Incubate at room temperature for 10 min.
3. Measure the absorbance at 595 nm.
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4. Incubate at room temperature for 10 min.
5. Use the standard below to calculate the protein concentration.
Standard curve generated use bovine serum albumin (BSA)
Protein Assay BSA
y = 0.0577x + 0.0345
R2 = 0.9993
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Activity Assay (Methioninase Enzyme)
Mix:
o 100 µL of potassium phosphate buffer 0.5 M at ph 8
o 125 µL of L-methionine 0.1 M
o 50 µL of pyridoxal phosphate 0.1 mM
o 225 µL of enzyme sample (for the blank, replace by purification buffer)
Methionine Methanethiol + 2-ketobutyrate
H2O NH4+
P.P : Pyridoxal phosphate (co-factor)
Enzyme+P.P
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1. Incubate the mixture at 37°C for 10 min.
2. Add 62.5 µL of 50 % (w/v) trichloroacetic acid to terminate the reaction.
3. Centrifuge at maximum speed for 2 min.
4. Mix :
• 250 µL of the supernatant
• 500 µL of sodium acetate buffer 1 M at pH 5
• 200 µL of MTBH 0.1% (MTBH: 3-Methyl-2-benzo-thiazolinone
hydrazone hydrochloride hydrate.)
5. Incubate at 50°C for 30 min.
Cool the solution at room temperature. Measure the absorbance at 320 nm against the
blank. Use the standard below to calculate the methioninase unit concentration in the
sample.
Standard curve is generated using -Ketobutyrate and MTBH
Activity Assay Standardy = 1.1924x + 0.2769
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Definition of unit: One unit of enzyme is defined as the amount that catalyzes the
fomation of 1 µmol of -ketobutyrate per minute. Specific activity is expressed as units
per milligram protein.
SDS-PAGE Analysis of Proteins
Components Stacking gel
4%
Separating gel
12%
dH2O 3.63 ml 3.34 ml
1.5 M Tris-HCL pH 8.8 - 2.5 ml
1 M Tris-HCL pH 6.8 625 µl -
10 % (w/v) SDS 50 µl 100 µl
Acrylamide (29%) Bis (1%) 667 µl 4 ml
Ammonium persulfate 10% 25 µl 50 µl
TEMED 5 µl 10 µl
Total 5 ml 10 ml
1. Reagents required for the casting of mini-SDS-PAGE gels
2. Assemble the glass plates on the gel casting stand and fill with water to ensure that
they are sealed.
3. Mix the components of separating gel, adding the TEMED last. Mix well and
immediately fill the glass plates, leaving a 1.5 cm gap at the top (for the stacking gel).
4. Immediately add 1 ml of isopropanol on top of the gel to prevent oxygen from
inhibiting the polymerization. Wait 20 min for solidification.
5. Pour off the isopropanol and rinse with dH2O to remove any residual isopropanol.
Mix the components for the 4% staking gel and pour on top of the separating gel.
Insert the well-comb and wait 20 min for solidification.
6. Preheat a water bath to 100ºC.
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7. Prepare the SDS-PAGE loading buffer by diluting -mercaptoethanol 20 X (1:20)
with the SDS-blue buffer.
8. For a 4 ml culture with an approximate OD600 of 0.8, add 600 µl of SLB to the cold,
centrifuged pellet. Suspend pellet in the SLB by vortexing.
9. Immediately heat the sample to 100ºC for 2 min.
10. Allow the samples to cool down for at least one min beforeloading the gel. Assemble
the solidified gels in the buffer chamber. Fill the chamber with running buffer.
11. Load 10 µl of each protein sample into the wells. Run the gel at a constant voltage of
165 V for about 1 hour, or until the dye reaches the bottom of the gel.
12. Cut off the stacking gel and discard it.
13. Stain the separating gel with a staining solution containing 45 % (w/v) dH2O, 45%
(w/v) methanol, 10 % (v/v) acetic acid, and 0.25 % (w/v) Coomassie Brilliant Blue
R250. Stain for 1 hour with gentle shaking. If shaking is not possible, an overnight
incubation will be sufficient.
14. Pour the stain back into its container (it can be re-used several times) and rinse the
tray with water. To remove the extra stain on the gel, use a destain solution (same as
the staining solution, but without the Coomassie Blue). Protein bands will be visible
immediately on a light table.
Western Blot
1. Soak the PVDF membrane first in methanol. Thoroughly wet the membrane with
water. Make the sandwich with sponge, 3 sheets of whatman, gel, PVDF
membrane, whatman paper, sponge in order with BLACK down. gel on black side
and membrane on clear side.
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2. Face BLACK to BLACK and RED to RED and run the transfer for 2 h 30 min at
80 V (make sure it shows, approx. 1.5 amps for 2 transfers and 0.7-.75 amp for 1
gel)
3. Remove sandwich in order, note the protein side.
4. Use ponceau if needed, just about that the blots get properly rinsed.
5. Rinse off the ponceau, by washing it with 1XTBS, adding a single drop of NaOH.
6. Block in 5 % milk 1XTBS-t for 1 hr.
7. Wash 3 × with 1 × TBS-t;
8. 1st wash for 15 min.
9. 2nd wash and 3rd wash 5 min each, Rinse off thoroughly.
10. Add 1o primary Ab,
Take proper care to avoid any bubbles between the blot and the inner side of the
hybetube.
11. Remove 1o Ab
12. Wash 3 × with 1 × TBS-t 
13. 1st wash for 15 min.
14. 2nd wash and 3rd wash 5 min each, Rinse off thoroughly.
15. Add 2o Ab,
Take proper care to avoid any bubbles between the blot and the inner side of the hybetube.
Protocol for Fusion Protein Injection in Nude Mice
1. Take the cart containing balance, dessicator container (with lid), gloves, isofuran,
alcohol swabs, and forceps to animal room.
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2. Turn on the light and blower of the hood and make sure that rooms are locked
3. Clean the surface of the hood with alcohol.
4. Take the balance and the green container into the hood.
5. Prepare the fusion protein sample injections into appropriate number of injections.
6. Keep the injections ready for use.
7. Take the green container onto the balance.
8. Take the cotton swabs and one drop of isofuran and drop the cotton swab into the
green container.
9. Take the mouse and drop into the dessicator container then wait until it becomes
unconscious. Measure the weight of the mouse.
10. Measure the size of the tumor ( LxBxH) by vernier scale and take note of mouse
tag number.
Mice tag no L B H Weight
11. Clean the mouse skin with alcohol swab.
12. Inject the fusion protein into middle of the tumor slowly and mark the tail of the
mouse with the marker.
13. Repeat this for all the mice.
14. Clean the surface of the hood and clean all the containers with an alcohol swab.
CPRG Assay From Stratagene
1. Pipet 20 µl of cell lysate into the wells of a 96-well microtiter dish.Prepare a
blank (for zeroing the microtiter dish reader) by adding 20 µl of lysis buffer to a
well. Prepare the control for endogenous -galactosidase activity by adding 20 µl
of lysate from the mocktransfected cells to a well.
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2. Prepare 25× CPRG substrate by adding 1 ml of buffer A to a vial of CPRG
substrate. Mix the two components by inversion. Dilute the 25× CPRG substrate
to 1× CPRG substrate by adding 1 part of 25× CPRG substrate to 24 parts of
buffer A.
3. Add 130 µl of 1× CPRG substrate to each well for a final volume of 150 µl.
Record the time of CPRG substrate addition. Cover the dish with a microplate lid.
4. Incubate the reactions for 30 minutes or longer (up to 72 hours) in a 37°C
incubator until the sample turns dark red. The incubation period will vary.
5. Terminate the reactions by adding 80 µl of stop solution to each well. Record the
incubation period, which is the time expired between the addition of CPRG
substrate and the addition of the stop solution.
6. Note Because the CPRG substrate begins to oxidize after stopsolution is added,
perform step 6 within 2 hours.
7. Scan the microtiter dish in a microtiter dish reader at a wavelength of 570–595
nm. Use the blank to zero the microtiter dish reader. Alternatively, measure the
optical density (OD570–595) of the blank and subtract it from the OD570–595
value of each well of cell lysate.
8. Determine the protein concentration and the specific activity of the sample
Binding of Methioininase-Annexin V on Externally Positioned PS on the Surface of Cells
1. Grow MCF-7 breast cancer cells using DMEM media containing 10% FBS until
they reached 85 % confluence in T-75 flasks.
2. Count the cells using haemocytometer.
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3. Transfer cancer cells (5 x 104) to 24 well plates and grow until 85 % confluence is
reached.
4. PS was exposed on the surface of cells by the addition of hydrogen peroxide (1
mM). Treat cells with 100 µl wash/binding buffer containing the DMEM media
containing 1 mM of H2O2 for 1 h at 37 oC.
5. Fix the cells by adding 100 µl PBS buffer containing 0.25 % glutaraldehyde and
Ca2+ (2 mM).
6. Quench excess aldehyde groups incubating with 50 mM of NH4Cl (100 µl) for 5
min.
7. Prepare methioninase-annexin V fusion protein in wash buffer with an initial
concentration of 6.7 nM.
8. Do serial 2-fold dilutions of this concentrated fusion protein solution until final
concentration of 6.7 pM.
9. Add methioninase-annexin V (300 µl) to wells in the increasing concentration of
methioninase-annexin V.
10. For each concentration of methioninase-annexin, the experiment is done in triplets.
11. Incubate for 2 h.
12. Wash plates with wash buffer (300 µl).
13. Add 300 µl of primary antibody (rabbit anti-methioninase) diluted in wash buffer
(1:1000) and incubate for 12 h at 4 oC.
14. Wash plates with wash buffer (300 µl).
15. Add 300 µl of goat anti-rabbit IgG secondary antibody with HRP conjugated
(1:1000 dilution in binding buffer) to the wells and incubate for 2 h at room
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temperature.
16. Wash the plates with PBS (300 µl).
17. Add the chromogenic substrate O-phenylenediamine (OPD, 300 µl).
18. Wait for 30 min and transfer 100 µl of the supernatant to 96-well plates.
19. Measure absorbance at 450 nm.
Binding of Methioninase-Annexin V on Plastic-immobilized Phosphatidylserine
1. Phospholipids were received in chloroform and diluted further in chloroform to a
concentration of 50µg/ml.
2. Add 100 µl of above solution to wells of 96-well plates.
3. After evaporation of solvent in air (used laminar flow hood), block the plates for 2
h with 10 % fetal bovine serum diluted in PBS containing 2 mM Ca 2+ (binding
buffer).
4. Methioninase-Annexin V was diluted in binding buffer at an initial concentration
of 6.7 nM.
5. Do serial 2-fold dilutions of this concentrated fusion protein solution until final
concentration of 6.7 pM.
6. Add methioninase-annexin V (100 µl) to wells in the increasing concentration of
methioninase-annexin V.
7. The plates were incubated at room temperature for 2 h.
8. Wash plates with wash buffer (100 µl).
9. Add 100 µl Rabbit Anti L-Methioninase 1o antibody to these wells (1:1000
dilution in binding buffer) for 12 h at 4 oC.
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10. Wash plates with wash buffer (100 µl).
11. Add 100 µl of goat antirabbit IgG conjugated to HRP (1:1000 dilution in binding
buffer) 2 0 antibody to the wells for 2 h at room temperature.
12. Wash plates with wash buffer (100 µl).
13. Add 200 µl of O-phenylenediamine (OPD) solution (chromogenic substrate) to
the wells.
14. Wait for 30 min.
15. Measure the absorbance at 450 nm.
Notes:
• OPD was added at concentration of 0.4 mg/ml in phosphate citrate buffer with
sodium perborate capsule (Product number P4922).
• Reagents were added after four washings of plates with the binding buffer.
